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Abstract 
Over the past two decades, the use of antipsychotics has increased tremendously worldwide, 
and second-generation antipsychotics (SGAs) have been the main driver of this trend. The 
extensive use of SGAs for off-label purposes has raised concerns over their role in clinical 
practice. In particular, studies have revealed serious metabolic and cardiovascular effects, and 
evidence is lacking on SGAs’ effectiveness. Despite the concerns, the extent and pattern of SGAs’ 
off-label use is largely unknown within the context of the Canadian primary health care system. 
Using electronic medical record (EMR) data from 14 practices in southwestern Ontario, we 
investigated the number of patients who were prescribed SGAs in primary care for off-label uses 
between 2005 and 2015. Furthermore, we compared the history of diagnosis of the off -label 
population to this history of a reference population (non-SGA users) in the same setting. 
The majority of patients who were prescribed SGAs lacked records of approved indications 
(72%), and the medications appeared to be prescribed much more frequently for off- than on-
label uses in any given year in the study period. SGAs are reported to be prescribed off -label for 
a variety of conditions; in our data, SGA users in the off-label group were more likely to have a 
history of dementia, anxiety and depressive disorders, personality disorders, and substance 
abuse, which may have been the off-label indications for which the patients were prescribed 
SGAs in primary care. 
Our findings indicate a need to promote evidence-based prescription of SGAs as well as the 
provision of further evidence on their use in off-label indications. Although off-label use has 
often preceded and outstripped supporting evidence, we encourage the regulatory agency, 
pharmaceutical industry, and science community to implement innovative policies and solutions 
to address the off-label prescribing practice 
Keywords 
Off-label use, second-generation antipsychotics, SGA, atypical antipsychotics, primary care, 
quetiapine, risperidone, olanzapine, aripiprazole, trend 
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Summary for Lay Audience 
Second-generation antipsychotics (SGAs) are a group of medications that initially were tested 
for certain mental diseases (schizophrenia, bipolar disorders, etc.) and were officially assessed 
and received approval for market entry. Later, studies reported that these medications were 
used for conditions for which there is no standard treatment or for patients who did not 
respond well to standard medications. Such uses are called off -label as they are not officially 
assessed and approved in contrast to on-label uses (uses for approved conditions). Off-label use 
of existing medications may be a helpful option for certain patients but there are concerns that 
without enough experiments, there would not be enough information on how effective and safe 
these agents might be in off-label uses.  
We studied patients who were prescribed SGAs in primary care between 2005 and 2015 in 
southwestern Ontario and compared the history of their diagnosis with the non-SGA users. The 
majority of patients in our data (72%) lacked records of approved indications and seemed to be 
off-label users. Health conditions like dementia, anxiety and depressive disorders, personality 
disorders, and substance abuse seemed to be the off-label uses of SGAs in our data. 
Our findings show a need for further research in this area as well as further safe and effective 
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Chapter 1  
1 Introduction 
Health Canada has the authority to approve medications for sale in Canada. As part of the 
approval process, Health Canada evaluates clinical trials for the candidate medication to assess 
the safety and effectiveness profile and decide on market authorization approval. Once the 
approval is issued, Health Canada specifies “the population for whom the drug can be prescribed, 
the indication(s) the drug can treat, and the dosage(s) that can be administered” and any use 
beyond these criteria is classified as “off-label” use (1). This includes medication prescribed for 
an indication or subpopulation (e.g. children or nursing women) not specified in the approval 
document. Prescribing a medication at a dose outside of approved dosing recommendations is 
also considered off-label use.  
While Health Canada has the authority to evaluate medications and specify approved uses (on-
label use), it has no jurisdiction over how drugs are used in clinical practice. In other words, 
Health Canada has no legal authority over how physicians decide to prescribe medications for 
their patients. Off-label prescribing is legal in Canada and physicians are permitted to prescribe 
medications off-label if it is in the best interest of their patients. In fact, off-label prescribing is 
not an unapproved practice necessarily. Sometimes, not all indications that have been adequately 
studied are submitted to Health Canada for approval as Canada’s market may be seen 
economically smaller compared to other markets or the medication may have moved to generic 
status, and the license holder has little incentive to spend its resources to officially get any further 
approvals for expanded indications. Moreover, for patients who are refractory to the approved 
treatments or those in conditions where no approved treatment is yet available, off-label 
prescribing of existing treatments might be a helpful option. However, the safety and 
effectiveness of this approach remains controversial (2–6), and a lack of evidence on benefits and 
harms of most off-label uses is a constant challenge. For example, quetiapine regular tablets, one 
of the most commonly prescribed antipsychotics, has been approved1 for schizophrenia and 
bipolar disorders but is not formally evaluated by the proprietor for sleep disorders and 
consequently not approved for this indication. Clinical trials conducted by other researchers on 
this off-label indication since its market entry in 1997 are still limited, and none of them 
compared quetiapine with an active control (e.g. zopiclone). Yet this medication has been 
prescribed off-label for insomnia for the past two decades (7). If use of a medication is not 
evaluated for an indication and not supported by robust evidence, the efficacy could be more of a 
hope than an expectation. Safety and risk of adverse events would be a concern as well, especially 
when a medication is prescribed off-label for an unevaluated subgroup of the population (e.g. 
children or seniors). 
Concerns regarding off-label use arise partly due to the fact that this phenomenon is remarkably 
common: in a study of prescribing patterns in the United States, Radley et al (2006) showed that 
21% of medications commonly prescribed by outpatient physicians were for off-label indications 
 
1 Quetiapine extended-release (XR) tablet is approved for major depressive disorder as well as 
schizophrenia and bipolar disorders. 
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(8). However, this study likely underestimated the frequency of off-label prescribing, as the study 
only considered the indications for prescriptions, and off-label uses for unevaluated populations 
or dose ranges were not assessed. The prevalence of off-label use also varies in different 
therapeutic fields – for example, in Canada the prevalence of off-label use for unevaluated 
indications was reported to be 12.4% for gastrointestinal medications, 15.2% for ear, nose and 
throat medications, 66.6% for anticonvulsants, 44% for antipsychotics, and 33% for 
antidepressants (9).  
Among psychiatric medications, second generation antipsychotics (SGAs) are of particular 
concern due to reports of increasing use, both for approved and off-label indications. Over the 
past two decades, use of antipsychotics has increased tremendously worldwide (10–12), and 
SGAs have been the main driver of this trend (12–20) (12). In Spain, a four-fold increase in 
antipsychotic use was observed between 1985 and 2000, and SGAs contributed the most to this 
increase (19). In the United States, 0.1% of the population used a SGA in 1996-1997, whereas in 
2004-2005 this increased to 1.1%, which is more than seven-fold increase (21). In the United 
Kingdom, there was a nearly six-fold increase in total SGA prescriptions between 1996 and 2001 
in primary care (22). These data are consistent with trends in Canada, where the number of annual 
antipsychotic prescriptions increased more than two-fold between 1993 and 2002, with more than 
80% of prescriptions in 2002 for SGAs (18). Prescriptions for quetiapine in particular increased 
more than 300% between 2005 to 2012 across Canada (23). 
Although the estimates from various studies differ based on the time period and the specific 
outcome defined, almost all studies confirm the increasing trend in the use of SGAs since their 
entry into the market. Given that the prevalence of psychotic disorders has been fairly constant 
over the last two decades (24), three main reasons are discussed to explain this increasing trend 
and the widespread use of SGAs: 
1- First generation antipsychotics (FGA) were notorious for extrapyramidal related adverse 
events (such as tardive dyskinesia, Parkinsonism, akinesia, akathisia)(25), which made 
their use limited in clinical practice. SGAs were shown to have fewer extrapyramidal 
effects in trials and soon replaced first generation agents in treating psychotic disorders. 
They soon became first line treatments in psychotic disorders in clinical guidelines due to 
their relatively safer profile compared to FGAs (20). Their better tolerability has also led 
to a longer period of use (20). 
2- On-label indications for SGAs were extended, and they received approval for treatment 
of bipolar disorder later – consequently, a larger portion of patient populations were 
prescribed SGAs (20). 
3- Off-label prescribing of SGAs has significantly contributed to the increasing trends 
(11,14,26,27). In fact, some studies reported that SGAs are prescribed more frequently 
for off-label indications than approved indications (28,29). 
The extensive off-label use of SGAs has raised concerns regarding the role of SGAs in clinical 
practice, especially when post-marketing1 and other studies revealed significant metabolic, 
 
1 “Post-marketing surveillance (PMS) (also post market surveillance) is the practice of monitoring the 
safety of a pharmaceutical drug or medical device after it has been released on the market and is an 
important part of the science of pharmacovigilance.” (30) 
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cardiovascular, and other side effects (31–35). If the effectiveness of SGAs have not been 
demonstrated for off-label uses, widespread use potentially puts a broader portion of the 
population at risk for adverse events like weight gain, diabetes mellitus, and sudden cardiac death 
(36) for little or no benefit. Therefore, evaluating the off-label use of SGAs and associated 
diagnoses in our health care system will be an important contribution to the existing literature and 
will be the focus of this study.  
Using the data from 14 primary care practices in southwestern Ontario, we will add to the 
evidence in this field and improve our understanding of current situation in primary care, where 
many SGA prescriptions are generated (23) and yet are less investigated, especially for adult and 
senior populations. Using electronic medical record (EMR) data, we will explore the prevalence 
and factors associated with of off-label use of SGAs between 2005 and 2015. The following 
chapters report on previous works in this field, describe our methodology and results and discuss 
findings of the current study. 
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Chapter 2  
2 Literature Review 
This chapter presents the history and current definition of off-label use, the associated legal 
challenges, and the previous studies on the prevalence of off-label use, with a focus on off-label 
prescribing of SGAs in primary care.  
2.1 Off-label Use – History and Current Definition 
The term “off-label” originates from the medication labeling requirements of the United States 
(US) Food and Drug Administration (FDA). At early stages in 1938, safety was the only regulatory 
requirement for a new medication to be approved by the FDA. In 1962, effectiveness was added 
as another requirement for new medication approval (37). Manufacturers were required to 
provide evidence that a new medication candidate was shown to be safe and effective for a 
specific indication. The FDA then regulated the drug labeling with the intention to provide drug 
information to healthcare professionals and assist them in prescribing drugs appropriately. A 
summary of safety and effectiveness information became part of official FDA drug labels, and 
use of any FDA approved medication for an unapproved indication, population, dose or by a 
different dosage form was referred as off-label use (38). 
 Drug labels are updated and evolve over time in terms of adverse events, warnings, and 
contraindications, but updates occur less frequently for new indications (3). Beside the cost of 
new clinical trials, adding an additional indication for an already approved medication can be 
time consuming and costly to the proprietor. Additionally, revenues for the indication in the 
remaining patent protection period might not offset the cost, especially when prescribers are 
legally allowed to prescribe medications off-label and without the official approval requirements 
(3). 
The FDA’s regulatory approach and requirements were adopted later and followed by many 
governmental regulatory agencies across the world, including Health Canada, which has the 
authority to approve drugs and official drug labels for domestic sale in Canada. Yet medications 
do not necessarily receive the same exact approvals in every country. For example, olanzapine 
(Zyprexa) is approved for pediatric patients with schizophrenia or bipolar type I disorder by the 
US FDA, but it is not approved to be used in pediatric populations by Health Canada.  
2.2 Legal Issues 
In both the US and Canada, the FDA and Health Canada, respectively, have the authority to 
evaluate drugs and specify approved uses (on-label use), but they have no jurisdiction over how 
medications are used in clinical practice. In other words, they have no legal authority over how 
physicians decide to prescribe medications for their patients. Physicians are permitted to 
prescribe medications off-label, but if a legal claim arises (e.g. following an adverse effect), they 
must justify their action on available scientific evidence and show that it was in the best interest 
of their patients, otherwise the prescriber might be accused of medical negligence (38). 
Off-label use of available treatments was historically accepted because it gives clinicians the 
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flexibility to help patients who are not responsive to approved treatments or those who have a 
condition where no approved treatment is yet available (36). The logic of using medications off-
label in these situations relies on one of the following two major assumptions:  
• The common pharmacologic class effect assumption assumes that drugs in the same 
class share similar common effects. According to this assumption, if, for example, one 
SGA is approved for irritability with autistic disorder in pediatric populations, other SGAs 
with similar chemical structure and pharmacologic properties would be expected to 
have a comparable efficacy and safety profile in pediatric populations. 
• The common pathophysiologic pathway assumption assumes that conditions with 
mutual physiologic mechanisms and pathways could be treated with common treating 
agents: for example, metformin, an oral antidiabetic agent, is used in infertility 
treatment and to induce ovulation in women with polycystic ovary syndrome (PCOS) 
through its action on insulin level and controlling insulin effects on ovarian androgen 
biosynthesis (39). 
These assumptions are not always valid, and hence direct promoting of off-label use by 
pharmaceutical companies is illegal and prohibited in US and Canada. However, as Stafford 
argues (3), there are areas of this prohibition policy that are not completely defined or enforced. 
For instance, the pharmaceutical industry may take advantage of promotional activities such as 
continuing medical education, and may provide physicians with a journal article regarding an 
off-label use. Although this is considered a form of education, it could be potentially biased and 
partial as trials may have been selected from industry sponsored and placebo controlled trials of 
limited quality (3). The Zyprexa (Olanzapine) settlement is an example of off-label promotion: in 
2009 Eli Lilly agreed to pay US $1.4 billion in settlement for off-label promotion of Zyprexa for 
agitation, depression, and sleep problems, which was the highest corporate fine in history at the 
time (40). Zyprexa was only approved for schizophrenia and bipolar disorders at the time this 
occurred. 
2.3 Challenges in Assessing Off-label Prescribing 
The way that off-label use is defined and measured affects prevalence estimates; not all studies 
use a universal definition of off-label use, and researchers may limit their definition and 
measurement to off-label use for either unapproved indication, dose, or age category rather than 
considering all three aspects. The majority of the literature that we found on off-label use is based 
on retrospective studies in primary and secondary care practice that assess off-label use of 
medications for unapproved indications, with relatively fewer studies on other types of off-label 
use or in other settings. The accurate capture of diagnoses associated with the prescribed 
medication is the single major limitation in measuring off-label use in many retrospective studies. 
The following section provides estimates and gives an overall understanding of how common off-
label use is in practice. 
2.4 Prevalence of Off-label Prescribing  
Off-label prescribing is a widespread and common practice. Radley et al. (2006) showed that 
21% of medications commonly prescribed by outpatient physicians were for off-label indications 
in the US (8), but did not assess off-label uses associated with unevaluated populations or dose 
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range. A study by Lat et al. (2011) assessed both indication and dose range in adult patients in 37 
critical care units in the US and reported that 36.2% of medications were for off-label uses (41). 
In another study, Loder et al., (2004) studied prescriptions for adults in a headache specialty 
practice and reported that 47% of prescriptions were for off-label indications or doses (42). 
The prevalence of off-label use varies depending on several factors. For one, off-label use is 
more common in some fields than others. Medications used in psychiatry and neuropsychiatry 
tend to be used more frequently off-label than gastrointestinal medications (9). Off-label use 
also varies in different populations: medications are not usually pre-tested in nursing or pregnant 
women, and the majority of medication use is off-label in these populations. Children, seniors, 
and women also have a higher rate of off-label use compared to the adult male population. The 
time since medication approval also affects off-label use, as older medications are usually 
perceived as having a better-known safety and efficacy profile and are therefore used off-label 
more frequently. Prescribers’ characteristics may also have a role in off-label prescribing, with 
male and older physicians being more likely to prescribe medications off-label compared to 
female and younger physicians (43–45). 
For off-label prescribing to children, a study by Shah et al (2007) showed that 78.9% of patients 
discharged from pediatric hospitals were taking at least one medication for off-label age category 
regardless of the indication (46). A high prevalence of off-label use in children has also been 
reported in other studies, and it has been commonly argued that this is because children are 
typically excluded from drug trials (11,47–49). Both the FDA and the European Medicine 
Agency (EMA) introduced initiatives to encourage clinical research in pediatric populations, 
however their policies seem to have had only marginal effects on off-label use of medications in 
this age category (50). 
In the field of psychiatry, off-label use is more prevalent than most other clinical specialties 
(8,51–53). Chen et al. (2006) studied off-label use of antidepressants, anticonvulsants, and 
antipsychotics in Medicaid enrollees in Georgia and reported that among adult patients who were 
prescribed antipsychotics, 63.6% received at least one antipsychotic for an off-label indication. 
Off-label doses were not assessed in this study (54). Alexander et al. (2011) reported that visits in 
which antipsychotics were prescribed for off-label indications almost doubled from 4.4 million in 
1998 to 9 million in 2008 in the US (55); off-label doses and use in off-label age categories were 
not assessed in this study.  
In Canada, increasing trends in the use of SGAs for both on- and off-label uses have been 
examined in different clinical settings across various provinces, including Ontario, British 
Columbia, Manitoba, and Quebec. The majority of these studies focused on children and youth, 
and used health administrative databases as their data source. The following estimates are from 
Canadian studies on the off-label use of SGAs. 
Alessi-Severini et al. (2012) studied ten years of antipsychotic prescribing to children and 
adolescents in Manitoba and reported that despite the lack of approved indication in this 
population, the prevalence of antipsychotic use increased from 1.9 per 1000 in 1999 to 7.4 per 
1000 in 2008, and SGAs were the driver of this increasing trend. They reported that more than 
70% of antipsychotic prescriptions were written by family physicians, and the most common 
diagnoses linked to antipsychotic use were attention-deficit hyperactivity disorder (ADHD) and 
conduct disorders. They used health administrative data in Manitoba Population Health Research 
Data Repository to identify those who were prescribed antipsychotics. Diagnoses were obtained 
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through the use of International Classification of Diseases, ninth and tenth version, Clinical 
Modification codes (ICD-9-CM and ICD-10-CM) in medical claims. Their data source captured 
over 90% of outpatient prescriptions dispensed to Manitoban residents without limitations 
regarding drug coverage, and results could be considered representative of the general youth 
population of Canada (56).  
Bock et al. (2016) conducted a survey of 100 pediatricians and 421 family physicians in 2013 and 
assessed medication therapy for pediatric insomnia in southwestern Ontario. They reported that 
antipsychotics were one of the most commonly prescribed medications in children 6 to 12 years 
of age (57).  
Chow et al. (2017) studied off-label use of quetiapine for insomnia in the inpatient child and 
psychiatry unit, and reported that 11.5% of admissions received a prescription for quetiapine (58). 
They performed a retrospective chart review after they identified night-time prescriptions of 
quetiapine to assess indication and doses. 
Lachaine et al. (2014) studied healthcare resource utilization (HRU) and costs related to SGAs 
among children with ADHD who previously received stimulants in Quebec. They concluded that 
off-label use of SGAs was associated with increased HRU and costs. They used Quebec 
provincial health care claim data between 2007 and 2012 for their study (59). 
Ronsley et al. (2013), studied the antipsychotic prescription trends in children and adolescents in 
British Columbia (BC) from 1996 to 2011 and reported an exponential rise in SGA prescriptions 
due to extensive off-label use: the prevalence of SGA prescriptions increased 18-fold (from 0.33 
to 5.98 per 1000 population in the study period) and the most common diagnoses associated with 
antipsychotics were depressive disorders, hyperkinetic syndrome of childhood, and neurotic 
disorders. They reported that in 2010-2011, psychiatrists, family physicians and pediatricians 
provided 38.6%, 34.3%, and 15.6% of new antipsychotic prescriptions respectively. They used 
the BC medication registry of all outpatient prescriptions (BC PharmaNet) to identify 
prescriptions for antipsychotics, dose and quantity dispensed, duration of treatment, and 
prescriber information for each prescription. Diagnoses were obtained from a probabilistic 
linkage between prescriptions and ICD-9 codes in medical claims – for each patient, the last 
diagnoses from the prescribing physician before the prescription was dispensed was considered 
the diagnosis associated with the antipsychotic prescription (27).  
Iaboni et al. (2016) used linked databases at ICES and studied the changing pattern of sedative 
use in older adults (≥ 66 years) between 2002 to 2013 in Ontario . The data revealed a shift away 
from benzodiazepines toward the off-label use of low dose quetiapine and trazodone (an 
antidepressant agent) in both community and long-term care settings. Diagnostic data were not 
analyzed in this study, but researchers examined prescribed doses and concluded that the 
observed low dose pattern is likely consistent with the off-label use of trazodone and quetiapine 
for sedative effects (60). Lunsky et al. (2018) also used databases at ICES and studied a cohort of 
adult patients with intellectual and developmental disabilities (IDD) who were prescribed 
antipsychotic agents (both first and second generation) between 2010 and 2016 in Ontario. 
Antipsychotic users were identified through Ontario Drug Benefit (ODB) claims, which covers 
medication costs for people with IDD who are on a disability support program. They also 
investigated whether patients in the cohort had a history of psychiatric disorders in the two-year 
period before their first antipsychotic prescriptions. Although they did not classify antipsychotic 
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users to off-label and on-label users, they reported that almost one-third of users (28.9%) had no 
recorded psychiatric diagnoses (61).  
Peringsheim and Gardner studied dispensed prescriptions for quetiapine between 2005 and 2012 
and reported a 300% increase in quetiapine prescriptions by family physicians, from 1.04 million 
in 2005 to 4.17 million in 2012. Both risperidone and olanzapine prescriptions also increased by 
37.4% and 37.1%, respectively, over the study period. The study examined the diagnoses 
associated with quetiapine only and reported a 10-fold increase in off-label use of quetiapine for 
sleep disturbances. Mood disorders, psychotic disorders, anxiety disorders and sleep disturbances 
were reported as the top four diagnoses associated with quetiapine use. Researchers used two 
different databases in this study: first, they used IMS Brogan CompuScript database, which 
captures filled prescription data from more than 60% of retail pharmacies across Canada, to 
determine the quantity of antipsychotic prescriptions per year; second, they used the Canadian 
Disease and Treatment Index, which collects treatment data from a sample of office-based 
physicians (n = 652) in Canada, to report on diagnoses associated with quetiapine (23).  
Eguale et al. (2012) studied determinants of off-label prescribing to adult populations in primary 
care in Quebec from 2005 to 2009. They reported that among different classes of medications, 
off-label use was the highest for central nervous system medications: 66% for anticonvulsants, 
43.8% for antipsychotics, and 33.4% for antidepressants. They used data from an electronic 
health record (EHR) system, which included 113 primary care physicians in urban centers in 
Quebec and 50,823 patients. The researchers indicated that a major advantage of this database 
was the accurate capturing of diagnoses. Participating physicians were required to specify the 
therapeutic indication with every prescription by selecting from a list of on-label and off-label 
indications or writing in a free-text field, and this uniquely allowed for accurate documentation of 
off-label use, unlike most other retrospective studies that utilize health administrative data (9). 
Off-label dose were not assessed in this study, however. 
2.5 Concerns with Off-label Prescribing 
It has been argued that in most cases, little is known about the effectiveness and safety when a 
medication is prescribed off-label (8). Eguale et al. (2012) studied off-label prescribing in 
primary care in Quebec and reported that 79% of the off-label prescriptions lacked strong 
scientific support, defined as no randomized trial to justify off-label uses (9). Another study by 
the same group recently reported that off-label prescriptions lead to a 57% increase in adverse 
drug reactions when compared to approved uses (62).  
SGAs are used for a variety of off-label indications in psychiatry, such as depression, obsessive 
compulsive disorder, personality disorders, post-traumatic stress disorder, Tourette syndrome, 
behavioral problems in patients affected by dementia, autism, anxiety, ADHD, eating disorders, 
insomnia, and substance abuse (63). The Agency for Healthcare Research and Quality (AHRQ) in 
the US published a review on off-label use of SGAs in 2006, and later released an updated 
version in 2011. The original review (31) concluded that there was no high strength evidence on 
the efficacy of SGAs for any known off-label use of SGAs. The updated review in 2011 (63) 
assessed additional published studies in the literature and found that available evidence still did 
not support the use of SGAs for most off-label indications (Table 2-1). The report adds that 
evidence on optimal dosage, duration of treatment, and effect of age in the use of SGAs for off-
label indications is lacking as well (63). 
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Aside from the unknown efficacy, safety is another concern regarding off-label use of SGAs. The 
original AHRQ review reported on strong evidence of an increased risk of adverse events (e.g. 
mortality in seniors) following off-label use of SGAs. The updated version of the review 
calculated the number needed to harm (NNH) for some adverse events: risk of death NNH = 87; 
stroke NNH = 53 for risperidone; and extrapyramidal symptoms NNH = 10 and 20 for olanzapine 
and risperidone respectively. In April 2005 following analyses of 17 placebo-controlled trials, the 
US FDA issued a black box warning for off-label use of SGAs in elderly patients with dementia: 
the risk of death was about 1.6 to 1.7 times that of placebo with various cause of death (heart 
failure, heart-related sudden death, pneumonia) in this population (64). Increased risk of coronary 
heart disease and metabolic syndrome in patients treated with SGAs and some typical 
antipsychotics has also been reported in other studies (32,34,65)(66,67).  
The original AHRQ review estimated that Olanzapine users are 6.1 times more likely to gain 
weight compared to placebo users and 2.6 times more likely compared to FGA users. This 
conclusion remained unchanged in the updated version. Weight gain is also seen with most other 
SGAs, but less than olanzapine. Newcomer et al. (2002) reported glucose level elevation with 
olanzapine, clozapine, and risperidone in comparison with both untreated controlled subjects and 
those on first generation antipsychotics (68). Guo et al. (2006) also linked SGAs to diabetes and 
reported that clozapine (Hazard Ratio [HR]: 7.0, 95% CI: 1.7 to 28.9), olanzapine (HR: 3.2, 95% 
CI: 2.7 to 3.8), risperidone (HR: 3.4, 95% CI: 2.8 to 4.2) and quetiapine (HR: 1.8, 95% CI: 1.4 to 
2.4) all increase the risk of developing diabetes (69). The AHRQ report, however, concluded that 
evidence for endocrine and metabolic risks of SGAs are less certain (63). In 2017, Sagreiya et al. 
(2017) compared the safety of antipsychotics (first and second generation) in pediatric, adult, and 
geriatric populations and reported that the frequency and type of adverse events is different in 
each population. Diabetes is frequently reported as one of the adverse effects of using SGA in 




Table 2-1 Efficacy of Olanzapine, Risperidone and Quetiapine by Off-label Conditions 
 Olanzapine Quetiapine Risperidone 
Anxiety 
  Generalized anxiety disorder - ++ - 
  Social phobia + - No Trial 
Attention-deficit hyperactivity disorder 
  No co-occurring disorders No Trial No Trial + 
  Bipolar children No Trial No Trial No Trial 
  Mentally retarded children No Trial No Trial + 
Dementia 
  Overall + + ++ 
  Psychosis +- +- ++ 
  Agitation ++ +- ++ 
Depression 
  MDD - augmentation of SSRI/SNRI + ++ ++ 
  MDD - monotherapy - ++ No Trial 
Eating Disorders -- - No Trial 
Insomnia No Trial - No Trial 
Obsessive-compulsive disorder 
  Augmentation of SSRI + - - ++ 
  Augmentation of citalopram No Trial + + 
Personality disorder 
  Borderline +- + No Trial 
  Schizotypal No Trial No Trial +- 
Post-traumatic stress disorder +- + ++ 
Substance abuse 
  Alcohol - - No Trial 
  Cocaine - No Trial - 
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  Methamphetamine No Trial No Trial No Trial 
  Methadone clients No Trial No Trial - 
Tourette’s syndrome No Trial No Trial + 
++ = moderate or high evidence of efficacy; + = low or very low evidence of efficacy; +- = 
mixed results; - = low or very low evidence of inefficacy; - - = moderate or high evidence of 
inefficacy 
MDD: major depressive disorder; SNRI: serotonin norepinephrine reuptake inhibitor; SSRI: 
selective serotonin reuptake inhibitor 
Adapted from: Maglione M, Ruelaz Maher A, Hu J, et al. Off-label use of atypical 




2.6 Summary of Existing Literature and Current Gaps on 
Off-Label Use of SGAs 
Off-label use of SGAs, especially risperidone, quetiapine, and olanzapine, is reportedly common 
and widespread in various studies and in different subgroups of the population. Yet, the efficacy 
of SGAs for most off-label indications is not supported by strong evidence and concerns 
regarding their safety profile remain. This is of particular concern when a drug treatment is not 
supported by strong evidence – when the effectiveness of the drug is not established, the 
prescriber is not able to have a clear estimate of risk-benefit balance. Off-label prescribing in this 
situation would potentially put a broader patient population at risk of adverse events, while the 
benefit may not be realized. 
Despite concerns regarding the trends in prevalence of off-label use of SGAs, few studies have 
been done on this subject in Canada. These studies provided valuable data, but they had some 
limitations: the majority of the studies were restricted to a specific age group (children and 
adolescents) (27,56–59), or a specific antipsychotic agent (23,60). In Ontario, data are lacking on 
the current situation of off-label use of antipsychotics in primary care. There is a need to re-
evaluate and understand the current prevalence of off-label use of SGAs across age categories in 
primary care in Ontario. The current study includes all available SGAs in Canada and aims to 
describe patients of various age categories who received a SGA prescription from their primary 
care provider in Southwestern Ontario, and investigate their history of diagnoses to evaluate off-
label use of SGAs between 2005 to 2015. This will provide an updated insight to policy makers 
regarding the current patterns of off-label prescribing and potential points of intervention. 
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Chapter 3   
3 Methods 
3.1 Research Objectives 
The objectives of this exploratory1 study were: 
1) To quantify and describe off-label uses of SGAs among primary care patients in Southwestern 
Ontario between 2005 and 2015: 
Research Question 1: What proportion of patients were prescribed an SGA for off-label 
indications in the study population? 
Research Question 2: What are the age and sex characteristics of patients who were 
prescribed an SGA for off-label indications compared to the on-label and reference 
groups in the study population? 
Research Question 3: How is the off-label prescribing changing over time in the study 
population? 
2) To compare history of diagnoses for patients with off-label SGA prescriptions with the on-
label and reference group: 
Research Question 4: Which diagnoses are seen more or less frequently in the off -label 
group as compared with the reference group in the study population?  
Research Question 5: Is there an association between the commonly reported off -label 
uses of SGA in the literature and history of diagnoses of patients in the off -label group, 
when controlling for age and sex characteristics? 
3.2 Data Source 
The data for this study were derived from Deliver Primary Health Care Information (DELPHI) 
database. DELPHI is part of Canadian primary care sentinel surveillance network (CPCSSN) 
project2 and is a de-identified research database created from Electronic Medical Record (EMR) 
 
1 “Exploratory research is research conducted for a problem that has not been studied more clearly, 
intended to establish priorities, develop operational definitions and improve the final research 
design. Exploratory research helps determine the best research design, data-collection method and 
selection of subjects” (71) 
 
2 CPCSSN is the first pan-Canadian multi-disease public and population health surveillance system. Health 
information from electronic medical records in the offices of participating primary care providers (e.g. 
family physicians) is collected with the purpose of improving the quality of care for Canadians suffering 
from variety of chronic and mental and neurologic conditions: hyperte nsion, osteoarthritis, diabetes, 
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data from primary care practices in Southwestern Ontario. It was created for the purpose of 
improving practice, policy, and research in primary care (72). The DELPHI data includes 
information on patient characteristics (birth year, sex, postal code, etc.), encounter billing 
information, medication lists, physical examination, allergy intolerance, family history, 
laboratory tests, and procedures. One important advantage that DELPHI data has over other 
data sources (e.g. ICES) is that DELPHI contains fields in regards to the “prescribed medications” 
for individuals. This information was essential in conducting this study and assessing off-label 
uses of SGAs. 
The DELPI project is currently comprised of 14 primary care practices throughout southwestern 
Ontario and includes 60 primary care physicians, 64,377 patients, and 1,956,778 encounters. For 
the purposes of this study, the analyses were limited to data extracted between October 1, 2005 
and December 31, 2015. Records before October 2005 or after December 2015 were excluded 
as data prior or after the specified dates may not be as accurate or complete in DELPHI.  
Primary care physicians in DELPHI were recruited through a variety of approaches, as described 
in detail in previous literature (72). Although the physicians were not selected through a random 
sampling strategy, they are considered representative of Ontario family physicians by age and 
sex (Table 3-1). Although, in terms of practice location, participants in DELPHI were less urban 
compared to Ontario family physicians. Table 3-1 shows the age, sex, and rurality distribution of 
the physicians as of fourth quarter of 2015. Primary care in Ontario is provided through different 
paths and by various practitioners other than family physicians (e.g. nurse practitioners, 
dieticians, pharmacists, etc.). However, DELPHI merely had data on family physicians in the 
study period whereas no other type of practitioner was included. So DELPHI data reflects only a 
part of broad services in primary care in southwestern Ontario and this should be considered in 
any inference made beyond the data.  
  
 
chronic obstructive pulmonary disease (COPD), depression, Alzheimer’s and related dementias, epilepsy 






Table 3-1: Comparison of Family Physician Characteristics of the DELPHI Sample and Ontario 
Family Physicians 
Characteristics 
DELPHI Family Physicians (n=60) 
from October 1st 2005 to 
December 31st 20151 
Ontario Family Physicians 




44 years and under 22 (36.7%) 1275 (32.8%) 
45-64 years 13 (21.7%) 922 (23.7%) 
55-64 years 13 (21.7%) 957 (24.6%) 
65+ years 12 (20.0%) 687 (17.7%) 
Unknown 0 (0.0%) 42 (1.1%) 
Sex 
  
Male 36 (60.0%) 2098 (54.0%) 
Female 24 (40.0%) 1758 (45.3%) 
Practice Location3,4 
  
Urban/suburban 23 (38.3%) (78.9%) 
Small town 24 (40.0%) (12.4%) 
Rural 13 (21.7%) (4.8%) 
Isolated/remote 0 (0.0%) (0.8%) 
No Response 0 (0.0%) (3.1%) 
1 Not all physicians contributed 10 years of data.  Some were retired/deceased or left their practice site 
before 2015. 
2 We do not have data on age of DELPHI physicians. Year of graduation was used as a proxy for age, with 
the assumption that most graduates would be approximately 28 years at the time of graduation, and age is 
measured as of 2015, at the end of the database extract. 
3 Location is measured differently for both DELPHI and the NPS.  DELPHI location was classified using 
the city location and adapted from a Statistics Canada population definition.  (Urban 100K+, Suburban 30 -
99K, Small Town 4-29K, Rural <5000).   
4 The NPS asked physicians " with respect to your main patient care/practice setting, describe the 
population primarily served by you in your practice. " The physicians gave responses in percentages, and 
not number of patients. No definition was provided for the type of location. 
3.3 Data in DELPHI 
Data from several different EMR software products is structured in 34 different tables in DELPHI. 
Each table has a title and various fields (columns) of several data types (text, date, auto integer, 
boolean, number, etc.). Tables may be linked through certain key fields to access associated 
information on specific cases. For example, people who had records for Risperidone in the 
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“Medication” table may be linked with data in the “Patient” and the “PatientDemographic” 
table through the mutual key “Patient_ID” to obtain birth year, occupation , and highest level of 
education for those people. Certain fields in DELPHI tables (identified by “_orig” appended to 
their field names) contain original text in EMRs with no systematic modifications to unify the 
information across EMR vendors. To better organize and provide data for research, another type 
of field is created in DELPHI and distinguished by “_calc” suffix. In these fields, data from “_orig” 
fields are algorithmically coded and converted to a unified form. For example, in the 
“Medication” table, which contains data on prescribed medications for patients, the field 
“Name_orig” has the medication name exactly as it appears in the EMR: this field may read 
“Seroquel”, “Auro-Quetiapine 25mg”, “PMS-Quetiapine 50mg tablet”, etc. for essentially the 
same active ingredient “Quetiapine,” depending on the particular clinician and EMR software 
used. In the “Name_calc” field, in the same table, all such variations are converted to a unique 
medication name “Quetiapine” with no extra indicator regarding strength, form , or producer 
propriety name. The converting algorithm was not accessible to us to check for conversion 
accuracy but our visual inspection of data revealed that incorrect conversions existed. 
Consequently, we implemented measures to authenticate the conversion algorithm. 
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Table 3-2 presents a summary of the DELPHI tables which are relevant to the current study. 
Tables with data on laboratory tests, risk factors, allergy intolerance, etc. are not presented 
here. For the purpose of this study we investigated the described tables to assess how detailed 
and complete the data were with respect to our study objectives. As the data in EMRs is 
primarily recorded for care services and not for the research purposes, DELPHI  tables varied 
widely in proportion of missing or invalid data. Further challenges arose when attempting to link 
records across tables, because keys were not always present. For example, when trying to link 
the data from the “Billing” table to “Encounter” table by the mutual “Encounter_ID” key field, 
only 161 out of 61,172 encounters were matched for those who were prescribed any SGA in the 
study period. In fact, most “Encounter_ID”s in the “Billing” table were not present in the 
“Encounter” table. After the assessment, we decided to primarily use the “Medication” and 
“Billing” tables, as they contained the required information to match and link records had 
relatively more complete data than other tables in DELPHI.  
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Table 3-2 Summary of Tables in DELPHI 
Patient: a list of EMR patients whose primary provider is a consenting physician in the CPCSSN 
project 
 • Contains 64,337 patients 
• Fields: Patient_ID, Sex, BirthYear, OptedOut, OptedOutDate 
PatientDemographic: characteristics and demographics of the patients 
 • Contains 51,406 patients 
• Fields: Patient_ID, Occupation, HighestEducation, HousingStatus, Ethnicity, 
DeceasedYear, Site_ID, Network_ID, etc. 
• Less than 4% of patients had any data in above fields.  
Medication: all medications prescribed for the patient.  
 • Contains 1,311,156 records for 42,857 patients 
• Fields: Patient_ID, Encounter_ID, Reason, Name_orig, Name_calc, Strength, Dose, 
Frequency, DispensedCount, RefillCount, Site_ID, Network_ID, etc. 
• The field “Reason” contains no data. 
Billing: all billing data submitted to the province for the patient  
 • 2,933,604 billing records for 54,953 patients 
• Fields: Patient_ID, Encounter_ID, ServiceDate, DiagnosisText_orig, DiagnosisText_calc, 
DiagnosisCode_orig, DiagnosisCode_calc, DateCreated, Site_ID, Network_ID, etc. 
• The field DiagnosisText_orig contains no data 
DiseaseCase: patients with one or more of the index diseases: chronic obstructive pulmonary 
disease (COPD), dementia, depression, hypertension, diabetes, epilepsy, osteoarthritis, 
Parkinson’s disease 
 • Contains 22,283 patients 
• Fields: Patient_ID, Disease, DateOfOnset 
• Case detection algorithm was based on either history of billing codes or  medications 
history in respective DELPHI tables 
Encounter: all encounters of the patient 
 • 1,956,778 encounter records for 45,780 patients 
• Fields: Patient_ID, Provider_ID, EncounterDate, Reason_orig, Reason_calc, Site_ID, 
Network_ID, etc. 
• >45% of encounters had either missing or invalid data in the “Reason_orig” field  
• Only 240 of off-label users and 120 of on-label users had any record in this table 
EncounterDiagnosis: all diagnoses resulting from an encounter  
 • 107,539 records for 23,301 patients 
• Fields: Patient_ID, Provider_ID, Encounter_ID, DiagnosisText_orig, DiagnosisText_calc, 
Site_ID, Network_ID, etc. 
• Only 11 of off-label users and six of on-label users had any record in this table 
HealthCondition: all health conditions of the patient. 
 • Contains 32,714 records for 4,756 patients 
• Fields: Patient_ID, DiagnosisText_orig, DiagnosisText_calc, DateOfOnset, Site_ID, 
Network_ID, etc. 
• Only 77 off-label user and 31 on-label users were in this table 
MedicalProcedure: procedures performed on the patient 
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 • 424,160 records for 13,515 patients 
• Fields: Patient_ID, Name_orig, Name_calc, PerformedDate, Site_ID, Network_ID, etc. 
Referral: includes referrals made for the patient (only referrals made by this provider/practice 
are included; referrals made by specialists or other providers are not included)  
 • Contains 158,426 records for 20,586 patients 
• Fields: Patient_ID, CompletedDate, Name_orig, Name_calc, Site_ID, Network_ID, etc. 
3.4 Definition of Groups and Classification Criteria 
3.4.1 SGA in Canada and Approved Indications 
A list of SGAs was derived from the FDA website (73) and checked for availability in Canada 
through “Drug Product Database” on the Health Canada website  (74). Approved indications for 
each SGA were recorded based on official Health Canada drug monographs, which were 
accessed through electronic database of Compendium of Pharmaceuticals (E-CPS) (75). Table 
3-3 shows the available SGAs in Canada during the time period of the study and their approved 
indications for each age category as of September 2017. Although drug monographs evolve over 
time and new indications might be added to the list of approved indications in time, we 
conservatively chose to define off-label use based on current monographs (September 2017), 
even for uses in earlier years. It is possible though, that some true off-label uses may have been 
misclassified to on-label use due to this method. Moreover, this study defined off-label use 
based on indication, and off-label uses of SGAs as defined by age or unapproved dosage were 
not investigated in our analyses. For example, if quetiapine is used in children (unapproved 
population) for an approved indication (e.g. schizophrenia), then it was considered as on-label 
use. 
3.4.2 Mapping Approved Indications to OHIP Billing Codes 
DELPHI data contains Ontario Health Insurance Plan (OHIP) billing codes for each patient-
provider encounter. Approved indications of SGAs (as of September 2017) were mapped to 
OHIP billing codes to be used in on-label versus off-label classification of SGA users. Table 3-3 
shows the approved indications and corresponding OHIP billing codes.  
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Table 3-3: Approved Indications of SGAs 
SGA (Brand Name) 
Age 
Category 








• Bipolar Disorder 




• Schizophrenia (15-17 years) 
• Bipolar Disorder (13-17 years) 
Geriatrics  




Adult 295 • Treatment-resistant schizophrenia 
Pediatrics  • Clozapine is not indicated in pediatric patients 







• Depressive Episodes Associated with Bipolar I 
Disorder 
Pediatrics 295 • Schizophrenia (15-17 years) 







• Schizophrenia and Related Disorders1 
• Bipolar Disorder 
Pediatrics  • Olanzapine is not indicated in pediatric patients 




Adult 295 • Schizophrenia and related psychotic disorders1 
Pediatrics  • Paliperidone is not indicated in pediatric patients 









• Severe Dementia of the Alzheimer Type—
Symptomatic Management of Aggression and 
Psychotic Symptoms in patients with severe 
dementia of the Alzheimer type 
 
1 The indications wording is exactly as it appears in Canadian monographs; the monograph do not have any clarification regarding 
the “related psychotic disorders”. However, the DSM IV lists several conditions (Schizoaffective disorder, delusional disorders, brief 
psychotic disorder, shared psychotic disorder, etc) under the title “schizophrenia and related psychotic disorders” among which only 





• Bipolar Disorder—Mania 
Pediatrics  • Risperidone is not indicated in pediatric patients 
Geriatrics  
• Physicians are advised to assess risks and benefits 









• Bipolar Disorder: 
• Major Depressive Disorder (XR tablets only) 
Pediatrics  • Quetiapine is not indicated in pediatric patients 
Geriatrics  








• Bipolar Disorder 
Pediatrics  • Ziprasidone is not indicated in pediatric 
Geriatrics 
 • Ziprasidone is not indicated in elderly patients 
with dementia 
3.4.3 On-label and Off-label Classification 
To classify DELPHI patients into on-label, off-label, and reference group, the data in the 
“Medication” table were investigated to identify those who were prescribed at least one SGA 
between October 1st, 2005 and December 31st, 2015 (SGA users). Queries were generated to 
explore the Name fields in the medication table for brand and generic names of SGAs. The 
outputs from both fields were inspected to confirm true capture of SGA records. When an 
inconsistency was observed, the priority was given to the field that contained original EMR data. 
Patients who had no records for any SGA were classified as the “reference” group. SGA users 
then were classified to on-label or off-label based on the presence of approved indications 
(Table 3-3) in their history of OHIP codes in the “Billing” table.  
For the on-label versus off-label classification, we considered all available history of codes for 
each patient, regardless of the timing of codes. Therefore, a patient was classified as on-label 
even if the patient had any of the approved codes after receiving his/her first SGA prescription. 
This approach was taken for two reasons. Firstly, in EMR data billing codes that are restricted to 
a certain period of time may not be a complete reflection of patients’ medical conditions 
(76)(77). We hypothesized that providers may use codes for common health conditions more 
often, or they may record patients’ previously diagnosed conditions more frequently and 
underuse codes for rare or stigmatizing conditions (e.g. Schizophrenia). In this situation, 
considering a complete history of billing codes would provide a more comprehensive picture of 
patients’ medical conditions than considering a time-restricted history of codes. Secondly, 
although it was feasible to define an index date for each patient in the SGA users group and 
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investigate approved codes prior to the index date, it was not possible to define an index date 
for patients in the reference group. Comparing the distribution of codes prior to the first SGA 
prescription in the off-label or on-label group to the distribution of all codes in the reference 
group could potentially be a source of information bias, as the reference group would have 
more complete data in such a comparison. 
3.5 Definition of Variables 
Age: The age for each patient was calculated as of December 31, 2015. Although this might have 
led to some misclassifications, choosing any other time point for age calculations would lead to 
negative measures for some patients. Three age categories were defined based on current age 
classification in official drug monographs:  
-Children and Adolescents: age less than 18 years 
-Adults: age greater than or equal to 18 and less than 65 years 
-Seniors: age greater than or equal to 65 years 
Age was used as a categorical variable (Children, Adults, Seniors). 
Number of visits: The number of visits for each patient was obtained from the billing table in 
DELPHI. Billing records occurring on the same day were considered one in-office visit. More than 
one billing record per day was likely due to multiple services related to the same visit. 
To calculate the median number of visits per year within each group (on-label, off-label, 
reference), the total number of visits for each patient in DELPHI was extracted and divided by 
the period of time (in years) between the first and last visit in DELPHI, and then the median visits 
were calculated. Interquartile range (IQR) was also calculated for each group. Patients with only 
one visit were not included in this analysis as the first and last visit in this case would be the 
same. 
Number of first SGA prescriptions: The annual number of first SGA prescriptions were inferred 
from the data in medication table in DELPHI. This table contains prescribed medications and 
respective dates. For each patient, the oldest record of any SGA was considered the first SGA 
prescription, in contrast to subsequent refill prescriptions. There were two limitations regarding 
this classification: First, some patients switched from one SGA to another during their presence 
in DELPHI and therefore had two or more starting records, one for each different SGA; in these 
cases, the oldest record was considered to be the first SGA prescription, and subsequent 
changes to other SGAs were ignored. Second, the data did not allow us to check for 
prescriptions started by psychiatrists or other secondary care specialists; it is plausible that a 
proportion of what we classified as the first SGA prescriptions were in fact refill continuation of 
treatments that were initiated by specialists at earlier time. 
Sex: The sex for each patient was obtained from the “Patient” table in DELPHI. The field “Sex” 
had only “Female” and “Male” values and no other sex orientation was recorded in DELPHI. The 
sex was used as a binary variable (male, female). 
History of Anxiety: History of anxiety for each patient was modeled as a dummy variable based 
on the presence or absence of OHIP diagnostic code 300 in the billing records. 
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History of Attention Deficit and Hyperactivity Disorders (ADHD): History of ADHD for each 
patient was modeled as a dummy variable based on the presence or absence of OHIP diagnostic 
code 314 in the billing records. 
History of Dementia: History of dementia for each patient was modeled as a dummy variable 
based on the presence or absence of OHIP diagnostic code 290 in the billing records.  
History of Major Depressive Disorder (MDD): History of MDD for each patient was modeled as 
a dummy variable based on the presence or absence of OHIP diagnostic code 311 in the billing 
records.  
History of Eating disorders, Sleep disorders, Tourette's syndrome: History of mentioned 
conditions for each patient was modeled as a dummy variable based on the presence or 
absence of OHIP diagnostic code 307 in the billing records. 
History of Post-Traumatic Stress Disorder (PTSD): History of PTSD for each patient was modeled 
as a dummy variable based on the presence or absence of OHIP diagnostic code 309 in the 
billing records. 
History of Personality Disorder (PD): History of PD for each patient was modeled as a dummy 
variable based on the presence or absence of OHIP diagnostic code 301 in the billing records. 
History of Substance Abuse: History of substance abuse for each patient was modeled as a 
dummy variable based on the presence or absence of OHIP diagnostic code 304 in the billing 
records. 
3.6 Missing Data 
The completeness of the data is an important consideration when analyzing EMR-derived data. 
As mentioned before, various fields in DELPHI tables have missing data. This might be due to the 
fact that no data was recorded originally in the EMR. It could also be a function of the way 
DELPHI was assembled: data is extracted remotely from several different EMRs using a newly 
developed process, and the data were unified to a common standard. There are sometimes 
problems ensuring complete data come into the database in a unified way, and errors can arise 
in recoding algorithms.  
In our study, completeness of six data fields was evaluated for our analyses: 
“DiagnosisCode_calc” and “ServiceDate” in the “Billing” table, “Sex” and “BirthYear” in the 
“Patient” table, and “Name_calc” and “StartDate” in the “Medication” table . Forty percent of 
records in the billing table (980,693 out of 2,471,189 records) had missing “DiagnosisCode_calc” 
(which itself mainly resulted from the missing or invalid values in the DiagnosisCode_orig field), 
and 7% and 22% of patients in DELPHI had missing sex and birth year, respectively. Data in the 
“Name_calc” was almost complete with < 0.1% missingness, and data in the “ServiceDate” and 
“StartDate” were complete with no missing values. 
Records with missing diagnosis codes were excluded from our analysis as imputation techniques 
could not be reasonably used. Missing data on sex and age category, however, were handled 
using single and multiple imputation techniques. To do this, all recorded procedures and 
diagnosis (billing) codes in OHIP coding system were investigated to identify sex -distinguishing 
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conditions and procedures (Table 3-4 and Table 3-5); if a sex-distinguishing condition had an 
identical code with a non-sex-distinguishing condition, it was excluded from this list: for 
example, “Dysmenorrhea” and “Stress Incontinence” are both coded 625 in OHIP coding system 
and therefore could not be used as a sex distinguishing code for imputation. Patients with se x-
distinguishing conditions were first imputed by rule-based single imputation.   
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Table 3-4: Sex-Distinguishing Conditions and Procedures -Female 
OHIP Codes Description 
 Pap smear, Pregnancy test, Insert intra-uterine contraceptive devicea 
174, 180, 181, 
183, 184 
Malignant neoplasm of cervix, ovary or other female organs 
218 Uterine fibroid 
220 Ovarian cyst 
219 Cervical Polyp or other benign neoplasm of uterus 
256 Ovarian dysfunction, polycystic ovaries 
289 Adenitis cervical 
610 Cystic mastitis, fibro-adenosis of breast 
614 Salpingitis, oophoritis, or pelvic inflammatory disease 
615, 617 Endometriosis 
616 Cervicitis, vaginitis, cyst or abscess of Bartholin's gland, vulvitis 
618 Cystocele, rectocele, urethrocele, enterocele, uterine prolapse 
621 Retroversion of uterus, endometrial hyperplasia, other disorders of uterus 
622 Cervical erosion, cervical dysplasia  
623 Stricture or stenosis of vagina  
626 Disorders of menstruation (amenorrhea, hypermenorrhea or hypomenorrhea or 
menorrhagia) 
627 Menopause, post-menopausal bleeding 
628 Female infertility 
629 Other disorders of female genital organs 
632 Missed abortion 
633 Ectopic pregnancy 
634 Cystitis or pyelitis during pregnancy 
634 Complete or incomplete abortion 
635 Therapeutic abortion 
640 Haemorrhage in early pregnancy or threatened abortion 
641 Abruptio placentae 
642 Toxaemia of pregnancy 
642 Pre-eclampsia  
643 Vomiting as a complication of pregnancy 
644 False labour 
645 Prolonged pregnancy (post maturity pregnancy) 
646 Cervicitis, vulvitis, vaginitis, varicose veins, pelvic inflammatory disease, anemia or 
other complications during pregnancy 
650 Uncomplicated pregnancy or normal delivery 
651 Multiple pregnancy 
652 Unusual position of fetus 
653 Cephalo-pelvic disproportion 
653 Abnormal bony pelvis in pregnancy: 653 
656 Fetal distress in pregnancy 
658 Premature rupture of membranes in pregnancy 
660 Obstructed labour 
661 Uterine inertia  
662 Prolonged labour 
664 Perineal lacerations 
666 Post-partum haemorrhage 
667 Retained placenta  
669 Delivery with other complications 
671 Post-partum thrombophlebitis 
675 Post-partum mastitis 
677 Post-partum pulmonary 
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OHIP Codes Description 
752 Cervical hyperplasia  
a: Procedures in DELPHI are recorded by description and have no corresponding code. History of procedures for 
patients were investigated for sex distinguishing procedures by using procedure descriptions field. 
Table 3-5 Sex-Distinguishing Conditions and Procedures -Male 




Malignant neoplasm of prostate or other male genital organs  
257 Testicular dysfunction 
592 Prostate stone 
600 Benign prostatic hypertrophy (BPH) 
601 Prostatitis 
603 Hydrocele 
604 Epididymitis, Orchitis 
605 Phimosis 
606 Male infertility 
608 Undescended testicle, seminal vesiculitis or other disorders of male genital organs 
609 Newborn circumcision 
 
a: Procedures in DELPHI are recorded by description and have no corresponding code. History of procedures for 
patients were investigated for sex distinguishing procedures by using procedure descriptions. 
The remaining patients with missing sex or age category were imputed using a specific method 
of multiple imputation called multivariate imputation by chained equations (MICE).  MICE is 
flexible tool in managing missing data and is capable of handling data of different types (e.g. 
continuous, binary, or categorical) (78). 
Unlike single imputation, multiple imputation techniques create multiple complete datasets 
“based on the observed values for a given individual and the relations observed in the data for 
other participants, assuming the observed variables are included in the imputation model” (78). 
In this approach, each missing value is imputed multiple times based on available information in 
observed data; if available data are not informative regarding the missing variable, each 
imputation would vary substantially and the model will take into account the uncertainty in the 
imputations. On the other hand, if the missing value could be well predicted by the available 
data, the model will yield more coherent imputations and standard errors will be smaller (78). 
To select a subset of billing codes as predictors of sex and age category, the frequency of each 
code were compared across different strata of sex and age category for those with known sex 
and age. The codes with largest difference in distribution across different strata were assumed 
to be most predictive and selected as variables to be included in the imputation model. Table 
3-6 shows the selected billing codes that were used. 
Table 3-6: Conditions Used in the Multiple Imputation Model 
OHIP Codes Description 
057 Roseola  
079 Viral disease 
153 Malignant neoplasm of large intestine (excluding rectum) 
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OHIP Codes Description 
174 Malignant neoplasm of female breast 
212 Benign neoplasm of respiratory system 
216 Seborrheic wart or other skin conditions 
217 Benign neoplasm of breast 
220 Ovarian cyst 
226 Benign neoplasm of thyroid 
274 Gout 
290 Senile dementia  
313 Behavior disorders of childhood and adolescence 
332 Parkinson’s disease 
382 Otitis media  
401 Essential hypertension 
412 Arteriosclerotic heart disease 
428 Congestive heart failure 
435 Transient cerebral ischemia  
455 Hemorrhoids 
492 Emphysema 
571 Liver cirrhosis 
574 Gallstones 
585 Acute renal failure 
628 Infertility 
643 Vomiting as a complication of pregnancy 
600 Benign prostatic hypertrophy 
640 Threatened abortion 
646 
Cervicitis, vulvitis, vaginitis, varicose veins, pelvic inflammatory disease, anemia or 
other complications during pregnancy 
669 Delivery with other complications 
696 Psoriasis 
715 Osteoarthritis 
765 Low birthweight infant 
766 High birthweight infant 
773 Hemolytic disease of newborn 
769 Respiratory distress syndrome 
777 Perinatal disorders of digestive system 
779 Other conditions of fetus or newborn 
895 Family planning advice 
896 Immunization 
916 Well baby care 
3.7 Statistical Analyses 
We used descriptive statistics and frequency counts to describe the on-label, off-label, and 
reference groups. We applied Fisher exact tests to compare the frequency of each OHIP billing 
code between the groups. Due to the large number of comparisons made, the type I error rate 
was adjusted by Bonferroni-Holm method for multiple comparisons.  
The median number of visits per year for patients in the off -label and other groups were also 
calculated to compare use of primary care services and check for data contribution of each 
group in the study population.  
A logistic regression model was also developed to evaluate the association between the 
common off-label indications of SGA and a history of billing codes for our off -label and reference 
groups. The dependent variable was defined as group association (being in the off-label or 
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reference group), and dummy variables were created for common off-label indications for SGA 
and used as the independent variables. These indications were identified from previous 
literature and mapped to OHIP billing codes (Table 3-7). The logistic model was applied to five 
MICE-created datasets and pooled results are presented in the “Results” chapter.   
Table 3-7: Common Off-label Uses of SGAs and Respective OHIP Billing Codes 
OHIP Codes Description 
300 Anxiety disorders 
314 ADHD 
290 Dementia  
311 Major depressive disorder 
307 Eating disorders, Insomnia, Tourette's syndrome 
309 Post-Traumatic Stress Disorder (PTSD) 
301 Personality disorders 
304 Substance abuse 
As part of the data exploration, we also used a multi morbidity tool to investigate what 
combination of diagnosis are seen more frequently in the off -label group. This tool was 
developed by M. Bauer and K. Nicholson at The University of Western Ontario (London, Canada) 
to find either permutations or combinations (ordered clusters or unordered ones) among a sets 
of diseases (79). We observed that the codes for anxiety disorders and depressive disorders 
were recorded more frequently than other combinations in the off -label group. Consequently, 
we decided to use an interaction term for codes 300 and 311 in our regression analysis to assess 
the interaction effect of both conditions, compared to each condition alone.  All age- and sex-
stratified analyses presented in the “Results” chapter are derived from complete -case data with 
originally known birth year and sex. As a sensitivity analysis, the analyses were also applied to 
each of five imputed sets and findings were reported in the appendix section.  The data analyses 




Chapter 4  
4. Results 
4.1. Prescription Patterns of Second-Generation Antipsychotics 
in DELPHI 
Between October 1st 2005 and December 31st 2015, there were 52,138 unique patients in the DELPHI 
database. Of those, 827 (1.5%) had a record for at least one SGA prescription in their list of prescribed 
medications. Among SGA users, 596 patients (72%) had no history of a diagnostic code for an approved 
indication in their records and were classified as the off-label group, whereas 231 (28%) patients had a 
diagnostic code for an approved indication and were classified as the on-label group. The reference 
group (comparator group) consisted of the 51,311 patients in DELPHI with no record of an SGA 
prescription (Figure 4-1).  
Figure 4-1 Patient Classification in DELPHI Population 
 
Table 4-1 presents the frequency of first SGA prescriptions recorded in the DELPHI database for the off-
label and on-label groups by medication type. The majority of SGA prescriptions were for Quetiapine 
across both groups (off-label = 69%; on-label = 58%), followed by Risperidone and Olanzapine. These 
three medications accounted for 96% of all SGA prescriptions. Although Quetiapine and Risperidone 
prescriptions were more frequent in the off-label group, prescriptions for Aripiprazole were notably 
more frequent in the on-label group (off-label = 2% vs. on-label = 13%).  
 
Table 4-1: Frequency of First Second Generation Antipsychotic (SGA) Prescriptions by Medication Type 
Type of SGA 
(Year approved in Canada) 
Off-Label Group 
n = 596; n (%) 
On-Label Group 
n = 231; n (%) 
Quetiapine (1997) 410 (69%) 133 (58%) 
Risperidone (1993) 97 (16%) 31 (13%) 
Olanzapine (1996) 67 (11%) 31 (13%) 
52,138 
Patients in 
Bil l ing Table
827 had at least one 













Aripiprazole (2009) 11 (2%) 31 (13%) 
Ziprasidone (2007) 7 (1%) <6 (<3%) 
Paliperidone (2007) <6 (<1%) <6 (<3%) 
Clozapine (1991) <6 (<1%) <6 (<3%) 
Lurasidone (2012) 0 (0%)  <6 (<3%) 
Asenapine (2011) 0 (0%) 0 (0%) 
*Cell sizes less than or equal to 5 suppressed 
To compare the trends in off-label and on-label prescribing over time, the annual number of first SGA 
prescriptions were divided by total number of first prescriptions in each year. The results are presented 
in Figure 4-2. In any given year from 2005 to 2015, there was a higher number of first SGA prescriptions 
in the off-label group compared to the on-label group. In the off-label group, the ratio of first SGA 
prescriptions is relatively constant between 2005 to 2009 before a sharp increase during 2010, and then 
it falls gradually between 2011 to 2015. Although the ratio at peak in 2010 (43 per 10,000) is almost 4 
times greater than the smallest ratio in 2008 (13 per 10,000) among the off-label group, the trend in the 
on-label group is more steady with smaller fluctuations over the study period: the ratio increases slowly 
from 7 per 10,000 in 2005 to 16 per 10,000 in 2011 and then it declines to 5 per 10,000 in 2015. 
Figure 4-2: First Off-label and On-label Prescriptions by Year in DELPHI 
 
4.2. Description of the Study Sample  
The sex and age of the study sample, by group, are presented in Table 4-2. Across all groups, there were 
more females than males (off-label: 54% vs. 46%; on-label: 56% vs. 44%; reference: 54% vs 45.9%). In 
the off-label group, the mean age was 52.5 years (SD: 20.8) and higher than the mean for the on-label 
(49.4 years, SD: 16.4) and the reference groups (47.4 years, SD: 23.4). Almost half of patients were 























































First off-label First on-label
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reference group were children (<18 years), whereas only 1.5% of the off-label group were children. 
There were no children in the on-label group. Nearly 20% of patients in each group were older adults 
(≥65 years) (off-label = 21%; on-label = 16%; reference = 22%).  
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Table 4-2: Description of off-label, on-label and reference groups in DELPHI 
Group Characteristics Frequency (%) 
Off-label Users 







Age Mean (SD) 
Range 




Children and Youth (<18) 
Adult (18-64) 














Age Mean (SD) 
Range 




Children and Youth (<18) 
Adult (18-64) 




37 (16%)  
75 (33%) 
Reference Users 







Age Mean (SD) 
Range 




Children and Youth (<18) 
Adult (18-64) 







4.3. Comparison of Visit Frequency 
The billing records were used to calculate and compare median visit frequency in DELPHI. Age - and sex-
stratified results from complete case analysis are presented in Table 4-3 and  
 
 
Table 4-4.  
The median number of visits per year was smaller for patients in the off-label group compared to 
patients in the reference group (2.1 vs 2.3 visits per year respectively). When results were  stratified, 
male children and adults in the off-label group had a higher median compared to the reference group 
(male children: 4.0 vs 2.7; male adults: 2.1 vs 1.9). Male seniors in the off-label group had a smaller 
median (2.7 vs 2.9). For females, adult and seniors in the off-label group had a smaller median of visits 
per year compared to the reference group (1.9 vs 2.2, and 2.4 vs 2.9 respectively). This analysis was also 
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performed on each of five imputed datasets and results were generally similar to complete case 
analysis, with smaller differences in median visit frequencies seen between the off -label and reference 
groups. Results from analysis on imputed sets are presented in Appendix A. Overall, both off-label and 
reference groups seemed relatively balanced in terms of visit frequency and amount of data contributed 
to DELPHI. 
Table 4-3 Overall median for visit frequency per patienta 
 Median number of visits per year 
 Off-label group Reference group 
All age categories 2.1 (IQRb: 2.8) 2.3 (IQR: 2.9) 
aCalculated only for those with available birth year and sex data  




Table 4-4 Median visit frequency stratified based on age and sexa 
 Median number of visits per year 
 Male Female 
 Off-label Group Reference Group Off-label Group Reference Group 
Children 
 
4.0 (IQRb: 1.5) 2.7 (IQR: 4.2) - 2.6 (IQR: 4.2) 
Adult 
 
2.1 (IQR: 2.7) 1.9 (IQR: 2.4) 1.9 (IQR: 2.8) 2.2 (IQR: 2.4) 
Seniors 
 
2.7 (IQR: 3.9) 2.9 (IQR: 3.3) 2.4 (IQR: 1.7) 2.9 (IQR: 3.3) 
aCalculated only for those with available birth year and sex data 
bIQR: interquartile range 
 
4.4. Diagnoses Associated with the Off-Label Group 
Fisher’s exact tests were used to compare the frequency distributions of all recorded diagnostic codes 
between the off-label users and the reference group. The significance level was adjusted for multiple 
comparisons using the Bonferroni-Holm method, resulting in a family wise error rate (FWER) of 0.05.    
The analyses were stratified by age categories and restricted to those with available birth year 
(complete case analyses). Within the children and youth age category, we did not find any statistically 
significant differences in the frequency of diagnostic codes between those with off -label antipsychotic 
prescriptions and those in the reference group; however, the number of children and youth with off -
label prescriptions was very small (n = 9). There were significant differences in the frequencies of several 
diagnostic codes within both the adult and seniors age categories. The statistically significant results are 
presented in Table 4-5 and Table 4-6. 
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 For the adult age category, there were 42 significant differences in the frequency of diagnostic codes 
between the off-label and reference groups, ranging from 1% to 21%. Diagnostic codes for a variety of 
mental disorders were seen considerably more frequently in the off-label group, including depressive 
disorders (+21%), anxiety disorders (+12%), and the mixed code for habit spasms, tics, stuttering, 
tension headache, sleep disorders, anorexia nervosa, enuresis (+10%). Diagnostic codes for acute 
bronchitis (-10%), immunization (-13%), acute nasopharyngitis (-14%), and annual health examination (-
19%) were notably less frequent in the off-label group compared to the reference group. The frequency 
of alcohol-induced mental disorders, musculoskeletal conditions, disorders of female genital tract, skin 
conditions, conjunctiva disorders, and digestive symptoms were also significantly different across groups 
but were generally smaller in magnitude (≤6%). 
In the seniors age category, seven significant differences in the frequency of diagnostic codes between 
the off-label and reference groups were observed. The diagnostic code for dementia was 14% more 
frequent in the off-label group, whereas the diagnostic codes for hypertension (-19%) and unspecified 
disorders of back (-11%) were less frequent. Similar to the adult category, diagnostic codes for acute 
nasopharyingitis (-10%), acute bronchitis (-14%), immunization (-19%), and annual health examination (-
21%) were less frequent in the off-label group.
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Table 4-5 Fisher's Exact test on diagnosis distributions in off-label and reference groups – Adult (Only statistically significant results are 
reported, sorted by the difference in prevalence from those most in excess in the off-label group to those most in excess in the reference 
group.) 














Depressive disorder, not elsewhere classified 311 <0.001 <0.001 32.7% 11.4% 21 
Anxiety, dissociative and somatoform disorders 300 <0.001 <0.001 35.8% 23.5% 12 
Habit Spasms, Tics, Stuttering, Tension headache, 
Sleep disorders, Anorexia nervosa, Enuresis due 
to mental disorder 
307 <0.001 <0.001 13.8% 4.1% 10 
Drug dependence 304 <0.001 <0.001 11.0% 2.0% 9 
Joint, leg or muscle pain; symptoms involving 
nervous and musculoskeletal systems 
781 <0.001 0.001 22.6% 14.1% 9 
Paranoid Personality Disorder; Obessesive 
Compulsive Personality 
301 <0.001 <0.001 6.0% 0.4% 6 
Drug-induced mental disorders 292 <0.001 <0.001 5.3% 0.2% 5 
Alcohol-induced mental disorders 291 <0.001 <0.001 4.1% 0.2% 4 
Specific delays in development 315 <0.001 <0.001 3.8% 0.6% 3 
Other disorders of female genital organs 629 <0.001 0.006 3.5% 0.9% 3 
Myositis, Muscular Rheumatism, Fibrositic, 
myositis, muscular rheumatism... , unspecified 
neuralgia (7292) 
729 <0.001 <0.001 4.1% 0.7% 3 
Other nonorganic psychoses 298 <0.001 <0.001 2.5% 0.2% 2 
Sexual and gender identity disorders 302 <0.001 0.001 2.2% 0.3% 2 














Erythematous conditions 695 0.003 0.043 3.5% 1.3% 2 
Other deficiency anemias 281 0.003 0.039 1.9% 0.4% 1 
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Unspecified intellectual disabilities 319 0.002 0.033 1.3% 0.2% 1 
Dyspareunia, dysmenorrhea, premenstrual 
tension, stress incontinence 
625 0.004 0.049 
0.3% 2.6% 
-2 
Other cellulitis and abscess 682 0.003 0.039 0.3% 2.8% -2 
Contact dermatitis and other eczema 692 0.001 0.017 0.0% 2.3% -2 
Tetanus 37 <0.001 0.006 0.0% 2.7% -3 
Nondependent abuse of drugs 305 <0.001 0.002 0.0% 3.1% -3 
Disorders of conjunctiva 372 0.001 0.011 0.6% 3.9% -3 
Disorders of external ear 380 0.002 0.027 0.3% 2.8% -3 
Sprains and strains of wrist and hand 842 0.001 0.020 0.3% 3.0% -3 
Other diseases due to viruses and Chlamydiae 78 <0.001 0.006 0.9% 4.8% -4 
Inflammatory disease of cervix, vagina, and vulva 616 <0.001 0.008 0.9% 4.7% -4 
Amenorrhea, Hypermenorrhea, Menorrhagia, 
Oligomenorrhea, Menstruation disorders 
626 0.001 0.013 
2.5% 7.0% 
-4 
Atopic dermatitis and related conditions 691 <0.001 0.005 1.3% 5.4% -4 
Hirsutism, scar, or other disorders of skin and 
subcutaneous tissue 
709 0.002 0.027 
2.8% 7.0% 
-4 
Sprains and strains of shoulder and upper arm 840 <0.001 0.001 0.6% 5.0% -4 




845 <0.001 <0.001 0.0% 4.1% -4 














Sprains and strains of other and unspecified parts 
of back 
847 0.001 0.013 2.2% 6.5% -4 
Gastritis and duodenitis 535 <0.001 <0.001 0.0% 4.5% -5 
Other and unspecified disorders of back 724 0.003 0.041 7.5% 13.0% -5 
General symptoms including pyrexia of unknown 
origin, headache, vertigo, ataxia 
780 0.001 0.020 3.5% 8.1% -5 
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Sprains and strains of knee and leg 844 <0.001 0.001 0.9% 5.7% -5 
Acute sinusitis 461 <0.001 0.001 2.5% 8.6% -6 
Digestive symptoms including anorexia, nausea 
and vomiting, heartburn, dysphagia, hiccough, 
hematemesis, jaundice, ascites, abdominal pain, 
melena, masses 
787 0.004 0.050 10.1% 15.8% -6 
Acute bronchitis and bronchiolitis 466 <0.001 <0.001 0.9% 10.7% -10 
Immunization 896 <0.001 <0.001 1.3% 14.2% -13 
Acute nasopharyngitis [common cold] 460 <0.001 <0.001 2.2% 16.5% -14 




Table 4-6 Fisher's exact test on diagnosis distributions in off-label and reference groups – Seniors (Only statistically significant results are 
reported, sorted by the difference in prevalence from those most in excess in the off-label group to those most in excess in the reference 
group.) 














Dementias 290 <0.001 <0.001 19.2% 5.3% 14 
Acute nasopharyngitis [common cold] 460 0.001 0.038 4.8% 15.1% -10 
Other and unspecified disorders of back 724 <0.001 0.010 4.8% 16.3% -11 
Acute bronchitis and bronchiolitis 466 <0.001 <0.001 0.8% 15.2% -14 
Essential hypertension 401 <0.001 0.003 32.0% 50.9% -19 
Immunization 896 <0.001 <0.001 0.8% 19.7% -19 




The Fisher’s exact tests were also performed on each of five datasets with imputed age values to include 
patients with missing birth year data. The statistically significant results are presented in appendix B. In 
the adult category, results in all five imputed sets were largely consistent with the complete case 
analysis; nevertheless, in two imputed sets, cardiovascular symptoms (including chest pain, tachycardia, 
syncope, etc.) were 4% more prevalent in the off-label group, unlike the complete case analysis. 
In the seniors category, 39 to 44 statistically significant differences were detected. In all five imputed 
sets, the difference in prevalence of anxiety disorders was the highest between the off -label and the 
reference groups (25% to 26% more prevalent in the off-label group). The difference for dementia was 
the second highest (19% to 20% more prevalent in the off-label group). Unlike the results from the 
complete set, a substantial difference in the prevalence of cardiovascular symptoms was seen in all five 
imputed sets. This condition was 16% to 18% more prevalent in the seniors category, in the off-label 
group, and in all imputed sets.  
In the children category, although the analysis on complete set did not reveal any significant difference, 
a few differences are evident when the analysis was performed on imputed sets: hyperkinetic syndrome 
of childhood (ADHD) was 21% to 38% more frequent in the off-label group, in four out of the five 
imputed sets, whereas the code for well-baby care visits was 49% to 50% less frequent in the same 
group in all five imputed sets. The analysis on imputed sets also showed differences in some conditions 
that are specific to adults (e.g. “Menopausal and postmenopausal disorders”) or are uncommon in 
children (e.g., benign neoplasm of skin or disorders of back). Although various age -specific conditions 
were selected for the imputation process and to avoid age misclassification, such results show that 
some error was introduced into our imputation process. 
4.5. Factors Associated with Off-Label Use of Second Generation 
Antipsychotics 
Univariate and multivariate regression models were used to estimate the association between off -label 
use of SGAs and conditions most commonly reported to be off -label indications for SGAs in the 
literature. The multivariate models were fit to each MICE-imputed dataset, and results from all sets 
were pooled together using the standard Rubin’s Rules. The odds ratios (OR), 95% confidence intervals 
(95% CI), and frequency distributions of each covariate for the univariate and multivariate models are 
presented in Table 4-7. 
The multivariate models suggest that anxiety disorders (OR = 2.7, 95% CI = 2.2, 3.3), senile dementia (OR 
= 5.02, 95% CI = 3.6, 7.0), depressive disorders (OR =3.9, 95% CI = 3.0, 5.1), personality disorders (OR = 
9.2, 95% CI = 5.8, 14.7), and drug abuse (OR = 3.43, 95% CI = 2.5, 4.7) were associated with a higher odds 
of being in the off-label group, controlling for other covariates. Children and youth had a lower odds of 
being in the off-label group (OR = 0.3, 95% CI = 0.2, 0.5). Sex, adjustment reactions (PTSD), and 
hyperkinetic syndrome of childhood (ADHD) were not significantly associated with being in the off -label 
group in either the unadjusted or fully adjusted models.  
Our multivariate models also suggest a significant interaction between depressive and anxiety disorders. 
The interaction term was significant showing that the OR of being in the off -label group for patients with 
either of anxiety disorders or depressive disorders depends on the level of the other condition: for those 
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with no history of anxiety disorders (300-0), the OR (311-1/311-0) would be equal to 3.89 while for 
those with a history of anxiety disorders (300-1), the OR (311-1/311-0) would be 3.89 * 0.43 = 1.67. 
(Note that comparing the group having codes for both anxiety and depressive disorders to the group 
who has neither gives an OR for (300-1,311-1/300-0,311-0) of 3.89 * 0.43 * 2.68 = 4.48.).
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Table 4-7: Factors associated with off-label use of SGAs 
Characteristics/ Common off-label uses of 
SGAs 
Frequency in the off-
label group (%) 
Frequency in the 
reference group (%) 
Univariate  







































300-Anxiety Neurosis, Claustrophobia, 
Obsessive Compulsive Neurosis, Suicide 
Tendencies, reactive depression, 
neurasthenia 
260 (44%) 10653 (21%) 2.95 (2.51-3.48) 2.68 (2.2-3.26) 
314- Hyperkinetic Syndrome of Childhood 11 (2%) 538 (1%) 1.77 (0.91-3.08) 1.64 (0.87-3.08) 
290- Senile dementia, presenile dementia 56 (9%) 780 (2%) 6.72 (5.01-8.85) 5.02 (3.64-6.93) 
311- Depressive or Other Non-Psychotic 
Disorder not classified elsewhere 
159 (27%) 4516 (9%) 3.77 (3.13-4.52) 3.89 (2.97-5.08) 
309-Adjustment Reaction 12 (2%) 956 (2%) 1.08 (0.58-1.84) 0.66 (0.37-1.19) 
301- Personality Disorders (Obsessive 
Compulsive, Paranoid, Schizoid) 
24 (4%) 182 (<1%) 11.79 (7.46-17.82) 9.24 (5.81-14.69) 
304 - Drug Abuse 47 (8%) 836 (2%) 5.17 (3.76-6.94) 3.43 (2.49-4.71) 
300*311 interaction term   - 0.43 (0.3-0.63) 
a: ORs are adjusted for sex, age and diagnoses codes 300 (Anxiety Neurosis, Claustrophobia, Obsessive Compulsive Neurosis, Suicide Tendencies, reactive 
depression, neurasthenia), 314 (Hyperkinetic Syndrome of Childhood), 290 (Senile dementia, presenile dementia), 311 (Depressi ve or Other Non-Psychotic 
Disorder not classified elsewhere), 309 (Adjustment Reaction), 301 (Personality Disorders: Obsessive Compulsive, Paranoid, Schizoid), 304 (Drug Abuse).  
b: Frequency for sex and age categories are presented based on the first imputed set 
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Chapter 5  
5 Discussion 
5.1 Prevalence of Off-Label SGA Use  
Over the ten-year study period, 1.5% of patients in DELPHI had records for at least one SGA prescription, 
and 72% of SGA users had no diagnostic record for approved indications. Our estimate of off -label use of 
SGAs was remarkably higher than what has been found in a comparable study in Quebec (43.8%) (9). 
The study by Eguale et al. was focused on 50,823 adult patients between 2005 to 2009 and was 
conducted in the primary care setting, similar to the current study. Their data were derived from an 
indication-based prescribing system that allowed for accurate and explicit recording of treatment 
indication for each written prescription. In the Eguale et al. study, however, antipsychotic agents were 
analysed as a single class and were not sub-categorized to first and second generation. This might be 
related to the lower estimate reported in their study as it has been argued that compared to SGAs, first 
generation agents were perceived to have higher risks of adverse events (20); consequently, this may 
have led to less frequent off-label use of first generation antipsychotics and a lower overall estimate. 
Nevertheless, we may have overestimated the prevalence, as our measurement of off-label use was 
mainly inferred based on history of medical records whereas Eguale’s study had a more accurate data on 
the indication for each prescription.  
Our estimate of off-label use (72%) was also higher than Chen et al. (2006) found in a somewhat 
different setting in Medicaid enrollees in Georgia in US. They found that 63.6% of 33,406 antipsychotic 
recipients among Medicaid enrollees (18 years or older) received at least one antipsychotic for an off -
label indication in 2001 (54). Although they used the same classification system to map to approved 
indications and to match with claim records as in the current study, their patient population was not 
limited to primary care patients and included claims from physicians, pharmacies, hospitals, and nursing 
homes. Within this study, the antipsychotic class-specific proportion of off-label use was not presented 
and instead the overall proportion for both first- and second-generation antipsychotics was reported. 
However, based on their report on top five prescribed antipsychotics, nearly 80% of total prescribed 
antipsychotics were for risperidone, olanzapine, and quetiapine, which suggest a significant portion of 
their estimate might have been related to those three second generation agents.  
The high prevalence of off-label use seen in our study, and in the previous literature, could be related to 
the lack of safe, effective, and approved treatments, as well as barriers regarding developing new 
medications for psychiatric disorders. Specifically: a) many psychiatric conditions are not yet well 
researched and understood; b) animal models are less applicable in psychiatry (80); and c) patients may 
not map to defined criteria and definitive and differential diagnosis is often hard to reach (36,80). 
Consequently, the design and conduct of trials to demonstrate the efficacy of psychotropic medications 
is challenging and many psychiatric conditions currently lack approved treatments (81). Moreover, 
manufacturers of current medications are often reluctant to conduct costly new trials with the hope of 
obtaining supporting evidence and follow time consuming regulatory procedures to add ne w indications 
to medication labels, especially once their medication is already in the market and could be prescribed 
off-label by prescribers (3,54).  
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In the children and youth category, only a small number of patients were prescribed any SGAs in our 
data (n=9), and none had history of diagnosis for an approved indication. Prevalent off-label use of SGAs 
in children has been reported in previous literature. As argued by Chen (2006), extensive off-label use of 
central nervous system medications in pediatric populations largely results from practical challenges and 
ethical limitations of conducting trials in this population (54). In a recent study in the US, Sohn et al. 
(2016) investigated national trends in the off-label use of SGAs in children and adolescent outpatient 
visits. Their findings suggest that among all visits in which a SGA was prescribed, 65% of the 
prescriptions were for a non-approved indication (82). 
In our data, 96% of first SGA prescriptions were for quetiapine, risperidone, and olanzapine in the off-
label group (69%, 16% and 11% respectively). Similar patterns have been reported in previous literature, 
suggesting that that older SGAs tend to be prescribed off-label more frequently (9) perhaps because 
they are better known and/or perceived safer in medical community compared to newer and less er 
known agents.  
Similarly, Peringsheim et al. (2014) studied dispensed SGA prescriptions in Canada between 2005 to 
2012 using pharmacy data, and reported that quetiapine, risperidone, and olanzapine were the most 
commonly prescribed antipsychotics by primary care physicians in the study period. They reported those 
three agents accounted for 80% of all SGA prescriptions (23). In another study, Alexander et al. (2011) 
used survey data from a random sample of office-based physicians in the US and reported quetiapine, 
risperidone, and olanzapine among the top four antipsychotics prescribed in 2008 (55). These three 
agents are also the most commonly prescribed antipsychotics for children and youth (≤ 18 years). 
Ronsley et al. (2013) reported that in 2010/11, 5,791 youths received antipsychotics in British Columbia 
and 96.1% of all antipsychotic prescriptions were for risperidone (48.0%), quetiapine (36.2%), and 
olanzapine (5.9%)(27). Alessi et al. (2012) also reported similar frequencies for over 2,100 youth in 
Manitoba (56). 
Although a wide range of estimates of off-label use of SGAs have been previously reported across 
various clinical settings, our findings are largely in agreement with other studies, which suggest that off-
label use of SGAs is prevalent in primary care practice. 
When we looked at the trend in SGA prescriptions over time, we observed that off -label users 
outnumbered the on-label users in any given year between 2005 to 2015. Off-label prescriptions had a 
relatively constant ratio of 15 per 10,000 first prescriptions for a period of four years (2005 to 2009) 
before it nearly tripled to 43 per 10,000 during 2010. The ratio then gradually decreased to 23 per 
10,000 in 2015. The sharp increase observed was primarily driven by first Quetiapine users, whereas first 
Olanzapine and Risperidone users had less contribution to the observed peak and decline.  A 300% 
increase in quetiapine prescriptions in primary care was previously reported between 2005 to 2012 by 
Pringsheim (23), however the increase in that study was gradual with a relatively constant slope and no 
peak as observed in the current study. In contrast to the first off-label prescriptions, the trend in the on-
label group was relatively flat with small fluctuations. It is not entirely clear why the number of first off-
label users increased rapidly during 2010 and declined thereafter. Regional and public mental health 
awareness campaigns in that time period is one factor that could potentially have contributed to the 
increasing trend. SGA regulatory related events or industry-sponsored promotional programs could be 
other potential contributing factors. 
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The increasing trend of first off-label users might be related to the approval updates for SGAs by the US 
FDA or Health Canada (Figure 5-1). Quetiapine was approved for bipolar disorders and MDD (for XR 
tablets) in adults in 2008 and 2009 respectively by Health Canada and for schizophrenia and bipolar 
disorders in adolescents in 2009 by the US FDA. Olanzapine also received similar approval updates in 
2009 by the US FDA. Although it is expected that these regulatory updates would have largely led to an 
increase in the first on-label prescriptions, the major increase occurred in the first off-label users during 
2010. One potential explanation for the observed peak in the first off-label users could be due to a high 
proportion of first Quetiapine users, who may have been prescribed regular tablets (instead of XR type) 
for MDD and consequently, they were classified as off-label in our analysis. Pharmaceutical promotional 
and advertisement activities could be another potential factor that contributed to the observed peak. 
Following the new approvals, the license holders often run awareness campaigns for prescribers which 
could potentially increase prescriptions for off-label uses as well. As discussed previously in the second 
chapter, regulations and policies regarding promotions of off-label use are not always well defined or 
enforced (3). 
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Literature regarding the trends over time in the use of SGAs are limited beyond 2010 – of existing 
studies, none show the gradual decline that we observed between 2010 and 2015. Similar to the 
increasing phase, the decline phase was mainly affected by quetiapine users. The trend we observed 
was also related to prescribing patterns among adults and the seniors, as our data had very few children 
and youth. Overall, the increasing trend for off-label use of SGAs between 2005 to 2015 seems to be 
similar to the overall trend for the off-label use of SGAs in children and youth in Canada (27).  
The proportion of female SGA users was slightly higher than male users across both off -label and on-
label groups in our sample, perhaps because some mental disorders are more prevalent in women (83), 
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and women are generally more likely to seek health care than men. In our data, adult and senior 
females in the off-label group generally had a smaller median number of visits per year than their male 
counterparts, whereas in the reference group the opposite was true. We investigated the median 
number of visits to see if any of the groups lacked data compared to others, but the difference was 
relatively small (between 0 to 4 visits per 10 years) and did not suggest any significant imbalance in visit 
frequency for adult and senior patients. Our data for children was very limited. 
 
5.2 Diagnoses Associated with Off-label Prescriptions 
We found that the frequencies of some diagnostic codes were significantly different across the off-label 
and reference groups. Codes for depressive and anxiety disorders were seen considerably more 
frequently in the adult off-label users (+21% and +12% respectively). A mixed code for habit spasms, tics, 
stuttering, tension headache, sleep disorders, anorexia nervosa, and enuresis was also seen more 
frequently in the same group (+10%). In the senior age category, the code for dementia (+14%) and 
cardiovascular symptoms (+4%) were more frequent in the off-label group. In the children and youth 
category, ADHD was 21% to 38% more frequent in the off-label group. The association between these 
conditions and the off-label use of SGAs may suggest that SGAs were prescribed with the intention to 
treat the above conditions in primary care. Consistent with our findings, previous literature has reported 
the following conditions as off-label uses of SGAs: depression, obsessive compulsive disorder, 
personality disorders, post-traumatic stress disorder, Tourette syndrome, behavioral problems in 
patients affected by dementia, autism, anxiety, ADHD, eating disorders, insomnia, and substance abuse 
(55,63).  
Although the associations observed do not reveal the actual indications for off -label use of SGAs in the 
study population, they do suggest potential indications of SGAs, common co-morbidities of the off-label 
users, or potential consequences of SGA use. Codes with lower frequency in the off -label group (e.g. 
immunization, acute bronchitis, annual health examination, unspecified disorders of back, well baby 
care visits) might show a lower access to care at some period in life or indicate a lower intention to seek 
care for perceived minor conditions in presence of mental conditions (e.g. depression). Additionally, 
prescribers’ coding behaviour may also have a role in the observed difference, as prescribers tend to 
record chronic conditions more often than codes for routine visits. 
Our multivariate model also confirmed that history of anxiety disorders, senile dementia, depressive 
disorders, personality disorders, and drug abuse were strong predictors for the likelihood of being in the 
off-label group, after controlling for other covariates. Antipsychotics are commonly used off-label for 
dementia, which is characterized by cognitive decline and memory loss and often associated with non-
cognitive neuropsychiatric symptoms like disordered mood, psychosis, inappropriate behavior, and 
motor symptoms (84). Among several medication classes used in dementia (antipsychotics, anxiolytics, 
antidepressants, anticonvulsant and mood stabilizers), antipsychotics seem to have better evidence in 
controlling these intrusive and debilitating symptoms (84). Risperidone, Olanzapine and Aripiprazole 
bring small but statistically significant benefit for these patients, whereas the evidence for Quetiapine is 
inconclusive (63,85). On the other hand, their risk profile is broad and brings major concerns. The use of 
SGAs in this population is shown to be associated with an increased risk of stroke, cardiac events, and 
mortality (33,84). The US FDA issued a black box warning regarding this in 2005, which was endorsed in 
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the same year by Health Canada (86,87). However, subsequent research in the US showed that the FDA 
warning has not led to major change in prescription patterns of antipsychotics among seniors with 
dementia (88,89). The fourth Canadian consensus conference on the diagnostic and treatment of 
dementia published a recommendation for family physicians stating that Risperidone, Olanzapine, and 
Aripiprazole should be considered for severe agitation, aggression and psychosis associated with 
dementia when there is a risk of harm to the patient or others and when the non-pharmacologic 
treatments were not effective. They graded this recommendation as a weak or conditional 
recommendation based on high-quality evidence (90). The latest American Psychiatric Association (APA) 
practice guideline on this subject also has a similar recommendation (85). 
Depression and anxiety disorders are prevalent psychiatric disorders that are both initially treated with 
two main class of medications as the first line options: selective serotonin and serotonin norepinephrine 
reuptake inhibitors (SSRIs and SNRIs) (91). However, nearly 50% of patients with depressive disorders or 
anxiety disorders fail to respond to the first line antidepressant and anti-anxiety medications (92,93). 
Due to their effects on the serotonin system (5HT1A and 5HT2A receptors), some SGAs have been seen 
as alternative options in refractory cases (91). The evidence currently available on their effectiveness in 
clinic varies, however. According to the AHRQ report, a moderate level of evidence suggests Olanzapine 
is not effective as monotherapy in depression and anxiety (GAD), whereas Quetiapine has been shown 
to be effective in some placebo-controlled trials. Risperidone and other SGAs were either not effective 
or were not examined in clinical trials (63). The Canadian Network for Mood and Anxiety Treatments 
(CANMAT) guideline for the management of anxiety and related disorders states that SGAs are 
considered as second-line, third-line, or adjunctive therapies in various anxiety disorders due to the risk 
profile (risk of diabetes, weight gain, etc.), limited available randomized trial data and lack of clinical 
experience with them (94). The CANMAT guideline on management of adults with MDD (95) do not 
recommend monotherapy with SGAs but reports that adjunctive use of aripiprazole, olanzapine, 
quetiapine, risperidone, and ziprasidone were shown to have small to medium effect sizes in Treatment-
Resistant Depression (TRD) and these agents may be used as adjunctive options. Although the level of 
evidence regarding this indication varies for SGAs, these agents generally have the most consistent 
evidence for efficacy in TRD. These findings were based on four independent meta-analyses (96–99) and 
a randomized clinical trial (100). The guideline suggests that the decision between switching to another 
antidepressant agent or adding an adjunctive agent (SGAs or other adjunctive agents) should be 
individualized and based on several clinical factors (95). 
The off-label use of SGA for personality disorders6 lies in the fact that some of these disorders (paranoid 
personality disorder, schizotypal personality disorder, borderline personality disorder, etc.) and 
schizophrenia can share some common symptoms (e.g. delusions, hallucinations, disorganized speech, 
etc.) (101,102) which are targeted by antipsychotics. Among ten personality disorders defined in DSM-5 
(102), SGAs are only studied in schizotypal and borderline personality disorders. According to the AHRQ 
updated review, Aripiprazole and Quetiapine have been shown to be effective, whereas Olanzapine and 
 
6 Personality disorders are a class of mental disorders characterized by enduring maladaptive patterns of behavior, 
cognition, and inner experience, exhibited across many contexts and deviating from those accepted by the 
individual's culture. These patterns develop early, are inflexible, and are associated with significant distress or 
disability (ref: DSM-5)  
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Risperidone have shown mixed results, all based on low and very low strength of evidence  (63). There is 
no approved medication available for this group of disorders yet.   
SGAs are used off-label for substance abuse disorders, although current literature in this area is very 
limited (63). For cocaine and amphetamine abuse, animal studies have shown conflicting results on the 
role of both first and second generation antipsychotics, but suggested that Clozapine (a SGA) may 
decrease cocaine and amphetamine self-administration (103–106). Use of Clozapine, one of the most 
effective SGAs, however, is limited in humans due to a potentially fatal agranulocytosis side effect. Few 
available human trials on the use of other SGAs have shown that Olanzapine, Risperidone, and 
Aripiprazole might be ineffective in treating cocaine and amphetamine abuse or dependence (107–109). 
Aripiprazole and Quetiapine also seem ineffective in treating alcohol dependency (109). 
5.3 Strengths of the Study 
This study was the first in Ontario to describe the off-label use of SGAs among primary care patients. The 
study was not limited to a certain antipsychotic agent or a certain age category, which has been the case 
in previous studies. We included all available SGAs and all age categories to provide a wider and more 
comprehensive description of off-label use in primary care.  
Using electronic medical record data and having access to a large sample of patients made it possible to 
study SGA users who typically comprise less than five percent of primary care patient population.  
5.4 Limitations of the Study 
One major limitation of the current study was our inability to capture the diagnosis associated with a 
SGA prescription within our data source. This limitation arises through several pathways.  
Firstly, we were not able to obtain information on visits to psychiatrists. It is possible that a proportion 
of patients who were assigned to the off-label group were originally prescribed a SGA for an approved 
indication by a psychiatrist, but the indication was not accurately reflected in the primary care EMR 
data. Although this might have potentially led to an overestimation of off -label use in primary care, the 
low frequency of referrals to psychiatrists among off-label users (2%) suggest that this is unlikely to 
substantially change our estimates.Second, we were not able to differentiate between providers’ failure 
to record a diagnosis and a true lack of a diagnosis or health condition. Providers may have had a 
different coding behaviours in regards to stigmatized diagnosis (like Schizophrenia) or when patient’s 
symptoms did not meet the complete diagnostic criteria. Physician performance in filling and recording 
problem lists, chronic disease lists, reason for each visit, and diagnosis for each visit ultimately shapes 
our data and determines how accurate and detailed the information is that is available to us. Physicians 
were also limited to record one billing code per visit for each patient and this might also have 
contributed to the partial recordings of health conditions. However, the on-label and off-label 
categorization we used considered all recorded diagnoses for each patient, instead of relying on single 
diagnosis associated with an encounter or within a certain time frame, which may reduce 
misclassification. 
Lastly, our methodology had also limitations in terms of missing data handling, age determination and 
code assignment to approved indications. 
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5.5 Implications for Practice  
The findings of this study add to the limited body of literature in this area and describe the extent of and 
trends in off-label use of SGAs, as well as the off-label indications in primary care. From a policy 
perspective, it is important to promote the evidence-based prescription of medications in practice. 
Findings from this study indicate that further research is required to produce evidence and fill current 
evidence gaps especially in regards to the efficacy of SGAs in off-label uses. There might also be a need 
to develop educational programs to communicate the widespread off-label use of SGAs in diverse 
populations, as well as to address a potential lack of evidence on their effectiveness and risk of adverse 
events to the primary care prescribers. Moreover, policymakers and public payers may draw on prior 
authorization or preferred medication list policies, if available, to alter their prescription pattern of SGAs 
toward evidence-supported agents. That said, the fundamental challenge is how to address the lack of 
evidence and determine who should produce evidence, and how, for a multitude of off -label uses in 
diverse populations and for less well-known mental conditions with low prevalence. Within the current 
framework, the pharmaceutical industry has little incentive to conduct costly trials after receiving initial 
approvals, and government research institutions have limited ability to assess numerous off -label uses. 
The regulator, on one hand, is wisely strict on evidence requirements for medication approvals, while on 
the other hand there is little control on off-label use of medications in practice. Regardless of whether 
the former is too restrictive or the latter is too relaxed and lenient, off -label users often lack evidence-
based treatments, and this challenge remains to be resolved.  
Further efforts in updating policies and exploring innovative solutions are required to enhance the 
evidence of off-label uses of SGAs. One potential solution may be fostering and expanding the use of 
real-world data and evidence (110) for safety and effectiveness assessments: If an evidence-based 
treatment is not available, policymakers can encourage new patient–provider encounters within the 
EMR framework in such a way that efficacy and safety indicators are defined, monitored, and recorded 
specifically in each follow-up for each off-label SGA order. Although there would be important 
methodological limitations to inferring data from such solutions, advances in study designs and 
statistical methods may support the acceptability of this approach (111). 
5.6 Conclusions 
The off-label use of SGAs is common in practice, and concerns have been raised regarding their safety 
and effectiveness in unapproved uses. Our study described patients who were prescribed SGAs with no 
history of approved indications in primary care in southwestern Ontario, and explored their history of 
diagnoses between 2005 to 2015 using EMR data. This study found that every 3 out 4 SGAs prescriptions 
in primary care may be prescribed for off-label indications, and in any given year in the study period 
SGAs are being prescribed more for off-label than on-label indications. Anxiety, depression, dementia, 
personality disorders, and drug addiction seem to be common off-label uses for SGAs and were 
significantly associated with the off-label group, when controlling for other covariates. Off-label 
prescribing of SGAs seems to have preceded the existence of compelling and supporting evidence on 
relevant effectiveness and safety. These findings are in agreement with previous literature from other 
provinces and outside of Canada. 
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Based on the findings of this study and the previous literature, further research is needed to produce 
evidence on comparative effectiveness and safety in various clinical populations. Policy makers are 
encouraged to facilitate and incentivize new psychotropic medication development to address the 
unmet need for safe and effective treatments for various mental disorders. Primary care physicians are 
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7.1 Appendix A 
The tables in this section represent the median visit frequencies of the off-label and reference groups for 
each of the five imputed sets. These analyses were performed to include patients with missing birth year 
and sex. Imputation sets are obtained by single and multiple imputation techniques which are described in 
detail in chapter 3.  
 
Table A-1 Median visit frequency stratified based on age and sex – Imputed Set 1 
 Median number of visits per year -Set1 
 Male Female 
 Off-label Group Reference Group Off-label Group Reference Group 
Children 
 
 4.2 (IQRa: 5.3) 2.9 (IQR: 4.3) 6.7 (IQR: 6.3) 2.9 (IQR: 4.4) 
Adult 
 
 2.3 (IQR: 3.5) 2.0 (IQR: 2.5) 2.3 (IQR: 3.7) 2.3 (IQR: 2.5) 
Seniors 
 
 5.6 (IQR: 7.1) 3.1 (IQR: 3.6) 3.5 (IQR: 8.6) 3.2 (IQR: 3.7) 




Table A-2 Median visit frequency stratified based on age and sex – Imputed Set 2 
 Median number of visits per year -Set2 
 Male Female 
 Off-label Group Reference Group Off-label Group Reference Group 
Children 
 
4.0 (IQRa: 3.7)  2.9 (IQR: 4.3) 5.0 (IQR: 1.8) 3.0 (IQR: 4.5) 
Adult 
 
2.4 (IQR: 3.5) 2.0 (IQR: 2.5)  2.3 (IQR: 3.7) 2.3 (IQR: 2.6) 
Seniors 
 
5.3 (IQR: 7.2) 3.1 (IQR: 3.6)  3.6 (IQR: 7.9) 3.2 (IQR: 3.6) 







Table A-3 Median visit frequency stratified based on age and sex – Imputed Set 3 
 Median number of visits per year -Set3 
 Male Female 
 Off-label Group Reference Group Off-label Group Reference Group 
Children 
 
2.5 (IQRa: 2.1) 2.9 (IQR: 4.3) 11.6 (IQR: 3.1) 3.0 (IQR: 4.5) 
Adult 
 
2.2 (IQR: 2.9) 2.0 (IQR: 2.5) 2.2 (IQR: 3.7) 2.3 (IQR: 2.6) 
Seniors 
 
5.7 (IQR: 7.2) 3.1 (IQR: 3.6) 3.5 (IQR: 8.2) 3.2 (IQR: 3.7) 
aIQR: interquartile range 
 
 
Table A-4 Median visit frequency stratified based on age and sex – Imputed Set 4 
 Median number of visits per year -Set4 
 Male Female 
 Off-label Group Reference Group Off-label Group Reference Group 
Children 
 
4.2 (IQRa: 5.3) 2.9 (IQR: 4.3) 6.7 (IQR: 2.5) 3.0 (IQR: 4.4) 
Adult 
 
2.3 (IQR: 3.5) 2.0 (IQR: 2.5) 2.2 (IQR: 3.7) 2.3 (IQR: 2.6) 
Seniors 
 
4.0 (IQR: 7.3) 3.1 (IQR: 3.5) 4.0 (IQR: 8.2) 3.2 (IQR: 3.6) 
aIQR: interquartile range 
 
 
Table A-5 Median visit frequency stratified based on age and sex – Imputed Set 5 
 Median number of visits per year -Set5 
 Male Female 
 Off-label Group Reference Group Off-label Group Reference Group 
Children 
 
3.9 (IQRa: 3.7) 2.9 (IQR: 4.3) 6.7 (IQR: 5.4) 2.9 (IQR: 4.4) 
Adult 
 
2.3 (IQR: 3.6) 2.0 (IQR: 2.5) 2.3 (IQR: 3.7) 2.3 (IQR: 2.6) 
Seniors 
 
4.5 (IQR: 7.4) 3.1 (IQR: 3.6) 3.4 (IQR: 7.3) 3.2 (IQR: 3.7) 






7.1 Appendix B 
The tables in this section compares the distribution of diagnosis codes between the off-label and reference 
groups for each of the five imputed sets. These analyses were performed to include patients with missing 
birth year and sex. Imputation sets are obtained by single and multiple imputation techniques which are 
described in detail in chapter 3. 
Table B-1 Fisher's Exact test on diagnosis distributions in off-label and reference groups – Imputed Set 
1 - Children (Only statistically significant results are reported, sorted by the difference in prevalence 


























Table B-2 Fisher's Exact test on diagnosis distributions in off-label and reference groups – Imputed Set 1 - Adult (Only statistically significant 





















Depressive disorder, not elsewhere classified 311 <0.001 <0.001 31.2% 11.1% 20 
Anxiety, dissociative and somatoform disorders 300 <0.001 <0.001 43.2% 23.8% 19 
Neuroses and Personality Disorders including Sleep disorders, 
Tension Headache, Habit Spasms, Enuresis due to mental 
disorder, Anorexia Nervosa 
307 <0.001 <0.001 14.1% 4.2% 10 
Drug dependence 304 <0.001 <0.001 10.2% 1.8% 8 
Joint, leg or muscle pain; symptoms involving nervous and 
musculoskeletal systems 
781 <0.001 0.003 22.3% 14.8% 8 
Drug-induced mental disorders 292 <0.001 <0.001 4.7% 0.2% 5 
Paranoid Personality Disorder; Obessesive Compulsive 
Personality 
301 <0.001 <0.001 5.5% 0.4% 5 
Myositis, Muscular Rheumatism , Fibrositic, myositis, muscular 
rheumatism... , unspecified neuralgia (7292) 
729 <0.001 <0.001 5.8% 1.0% 5 
Alcohol-induced mental disorders 291 <0.001 <0.001 3.4% 0.2% 3 






















Migraine 346 <0.001 0.018 5.5% 2.5% 3 
Symptoms involving urinary system 788 <0.001 0.011 4.7% 1.9% 3 
Other nonorganic psychoses 298 <0.001 <0.001 2.6% 0.2% 2 
Sexual and gender identity disorders 302 <0.001 0.003 1.8% 0.3% 2 
Alcohol dependence syndrome 303 <0.001 <0.001 2.9% 0.6% 2 
Other disorders of female genital organs 629 <0.001 0.005 3.1% 0.9% 2 
Other and unspecified anemias 285 <0.001 0.014 1.8% 0.4% 1 
Tetanus 37 <0.001 0.004 0.0% 2.4% -2 
Acute tonsillitis 463 0.003 0.049 0.3% 2.3% -2 
Disorders of conjunctiva 372 0.003 0.048 1.6% 4.6% -3 
Gastritis and duodenitis 535 <0.001 0.004 1.0% 4.8% -4 
Amenorrhea, Hypermenorrhea, Menorrhagia, Oligomenorrhea, 
Menstruation disorders 
626 0.002 0.034 3.7% 7.8% -4 
Atopic dermatitis and related conditions 691 0.001 0.028 2.4% 6.0% -4 
Hirsutism, scar, or other disorders of skin and subcutaneous 
tissue 
709 <0.001 0.011 2.4% 6.4% -4 
Other diseases due to viruses and Chlamydiae 78 <0.001 0.001 1.0% 5.2% -4 






















Acute bronchitis and bronchiolitis 466 <0.001 0.004 5.5% 11.4% -6 
Acute nasopharyngitis [common cold] 460 <0.001 <0.001 7.9% 19.7% -12 
Immunization 896 <0.001 <0.001 1.0% 13.3% -12 





Table B-3 Fisher's Exact test on diagnosis distributions in off-label and reference groups – Imputed Set 1 - Seniors (Only statistically significant 



















Anxiety, dissociative and somatoform disorders 300 <0.001 <0.001 45.2% 20.6% 25 
Dementias 290 <0.001 <0.001 25.6% 5.3% 20 
Cardiovascular symptoms including chest pain, 
tachycardia, syncope, shock, edema, masses 
785 <0.001 <0.001 32.2% 14.3% 18 
Digestive symptoms including anorexia, nausea and 
vomiting, heartburn, dysphagia, hiccough, hematemesis, 
jaundice, ascites, abdominal pain, melena, masses 
787 <0.001 <0.001 37.7% 21.5% 16 
Injury, other and unspecified 959 <0.001 <0.001 20.1% 4.2% 16 
Other ill-defined conditions of non-specific abnormal 
findings including asphyxia, excessive sweating, etc. 
799 <0.001 <0.001 30.2% 16.3% 14 
adverse effects Of surgical and medical care (e.g., wound 
infection, wound disruption, other iatrogenic disease) 
998 <0.001 <0.001 18.6% 6.5% 12 
Depressive disorder, not elsewhere classified 311 <0.001 <0.001 19.1% 7.8% 11 
Pneumonia, organism unspecified 486 <0.001 <0.001 18.6% 7.5% 11 
Joint, leg or muscle pain; symptoms involving nervous and 
musculoskeletal systems 
781 <0.001 0.015 31.2% 20.9% 10 




















Hematuria, Hemiplegia, or other disorders of urinary tract 599 <0.001 0.009 21.1% 12.2% 9 
Other nonspecific abnormal findings 796 <0.001 0.002 18.6% 9.3% 9 
Functional digestive disorders, not elsewhere classified 564 <0.001 <0.001 12.1% 4.4% 8 
Neuroses and Personality Disorders including Sleep 
disorders, Tension Headache, Habit Spasms, Enuresis due 
to mental disorder, Anorexia Nervosa 
307 <0.001 0.002 12.6% 5.1% 7 
Other disorders of ear 388 0.002693531 0.038 16.6% 9.8% 7 
Heart failure 428 <0.001 0.003 12.1% 5.0% 7 
Myositis, Muscular Rheumatism , Fibrositic, myositis, 
muscular rheumatism... , unspecified neuralgia (7292) 
729 <0.001 <0.001 8.0% 1.3% 7 
General symptoms including pyrexia of unknown origin, 
headache, vertigo, ataxia 
780 0.00315494 0.042 19.6% 12.2% 7 
Nonspecific findings on examination of blood 790 <0.001 <0.001 10.6% 3.7% 7 
Chronic airway obstruction, not elsewhere classified 496 0.003476031 0.044 13.1% 7.2% 6 
Other disorders of intestine 569 <0.001 0.002 10.1% 3.7% 6 
Symptoms involving urinary system 788 <0.001 0.005 10.1% 4.1% 6 
Other and unspecified malignant neoplasm of skin 173 <0.001 0.005 8.5% 3.1% 5 




















Iron deficiency anemias 280 0.002463139 0.036 9.0% 4.2% 5 
Other local infections of skin and subcutaneous tissue 686 <0.001 0.003 6.5% 1.8% 5 
Ill-defined intestinal infections 9 0.003506821 0.044 10.6% 5.3% 5 
Poisoning by other and unspecified drugs and medicinal 
substances 
977 0.001161212 0.020 9.0% 3.8% 5 
Diseases of esophagus 530 0.00140449 0.024 7.0% 2.7% 4 
Other and ill-defined sprains and strains 848 0.001502344 0.024 6.5% 2.4% 4 
Malignant neoplasm of trachea, bronchus, and lung 162 0.003104442 0.042 3.5% 0.9% 3 
Parkinson's disease 332 0.001726567 0.027 3.5% 0.8% 3 
Migraine 346 <0.001 0.008 4.5% 1.1% 3 
Other and unspecified disorders of the nervous system 349 0.00259542 0.037 4.0% 1.1% 3 
Intestinal obstruction without mention of hernia 560 <0.001 0.009 3.0% 0.5% 3 
Secondary malignant neoplasm of other specified sites 198 0.001755283 0.027 2.0% 0.2% 2 
Other nonorganic psychoses 298 <0.001 0.001 2.5% 0.2% 2 
Keratitis 370 0.003841363 0.047 3.0% 0.7% 2 





Table B-4 Fisher's Exact test on diagnosis distributions in off-label and reference groups – Imputed Set 2 - Children (Only statistically 
significant results are reported, sorted by the difference in prevalence from those most in excess in the off-label group to those most in 



















Hyperkinetic syndrome of childhood 314 <0.001 <0.001 40.0% 2.4% 38 





Table B-5 Fisher's Exact test on diagnosis distributions in off-label and reference groups – Imputed Set 2 - Adult (Only statistically significant 





















Depressive disorder, not elsewhere classified 311 <0.001 <0.001 30.8% 11.0% 20 
Anxiety, dissociative and somatoform disorders 300 <0.001 <0.001 43.2% 23.8% 19 
Neuroses and Personality Disorders including Sleep disorders, 
Tension Headache, Habit Spasms, Enuresis due to mental 
disorder, Anorexia Nervosa 
307 <0.001 <0.001 13.9% 4.3% 10 
Joint, leg or muscle pain; symptoms involving nervous and 
musculoskeletal systems 
781 <0.001 <0.001 23.4% 14.7% 9 
Drug dependence 304 <0.001 <0.001 10.3% 1.8% 8 
Paranoid Personality Disorder; Obessesive Compulsive 
Personality 
301 <0.001 <0.001 5.5% 0.4% 5 
Myositis, Muscular Rheumatism , Fibrositic, myositis, 
muscular rheumatism... , unspecified neuralgia (7292) 
729 <0.001 <0.001 6.1% 0.9% 5 
Diabetes mellitus 250 0.002 0.031 11.3% 6.9% 4 
Drug-induced mental disorders 292 <0.001 <0.001 4.5% 0.2% 4 
Cardiovascular symptoms including chest pain, tachycardia, 
syncope, shock, edema, masses 
785 0.002 0.037 11.1% 6.8% 4 






















Other nonorganic psychoses 298 <0.001 <0.001 3.2% 0.2% 3 
Specific delays in development 315 <0.001 <0.001 3.4% 0.5% 3 
Symptoms involving urinary system 788 0.002 0.037 4.5% 1.9% 3 
Dementias 290 <0.001 <0.001 1.8% 0.2% 2 
Sexual and gender identity disorders 302 <0.001 0.003 1.8% 0.3% 2 
Other disorders of female genital organs 629 <0.001 0.006 3.2% 0.9% 2 
Benign neoplasm of other parts of digestive system 211 0.003 0.046 0.5% 0.0% 1 
Other and unspecified anemias 285 0.003 0.045 1.6% 0.4% 1 
Unspecified intellectual disabilities 319 0.003 0.045 1.1% 0.1% 1 
Senility without mention of psychosis 797 0.003 0.045 1.1% 0.1% 1 
Tetanus 37 <0.001 0.006 0.0% 2.4% -2 
Acute tonsillitis 463 <0.001 0.008 0.0% 2.3% -2 
Disorders of conjunctiva 372 <0.001 0.017 1.3% 4.6% -3 
Gastritis and duodenitis 535 <0.001 0.004 1.1% 4.7% -4 
Atopic dermatitis and related conditions 691 0.001 0.030 2.4% 6.0% -4 
Hirsutism, scar, or other disorders of skin and subcutaneous 
tissue 






















Other diseases due to viruses and Chlamydiae 78 <0.001 <0.001 0.8% 5.3% -4 
Sprains and strains of knee and leg 844 0.003 0.045 3.2% 6.8% -4 
Family Planning 895 0.002 0.036 5.0% 9.5% -4 
Acute bronchitis and bronchiolitis 466 <0.001 0.006 5.8% 11.5% -6 
Acute nasopharyngitis [common cold] 460 <0.001 <0.001 8.7% 19.8% -11 
Immunization 896 <0.001 <0.001 1.1% 13.4% -12 





Table B-6 Fisher's Exact test on diagnosis distributions in off-label and reference groups – Imputed Set 2 - Seniors (Only statistically significant 





















Anxiety, dissociative and somatoform disorders 300 <0.001 <0.001 45.8% 20.7% 25 
Dementias 290 <0.001 <0.001 23.9% 5.3% 19 
Cardiovascular symptoms including chest pain, tachycardia, 
syncope, shock, edema, masses 
785 <0.001 <0.001 29.9% 14.0% 16 
Digestive symptoms including anorexia, nausea and vomiting, 
heartburn, dysphagia, hiccough, hematemesis, jaundice, 
ascites, abdominal pain, melena, masses 
787 <0.001 <0.001 35.3% 21.5% 14 
Injury, other and unspecified 959 <0.001 <0.001 17.9% 4.3% 14 
Other ill-defined conditions of non-specific abnormal findings 
including asphyxia, excessive sweating, etc. 
799 <0.001 <0.001 29.4% 16.5% 13 
Depressive disorder, not elsewhere classified 311 <0.001 <0.001 19.9% 7.8% 12 
adverse effects Of surgical and medical care (e.g., wound 
infection, wound disruption, other iatrogenic disease) 
998 <0.001 <0.001 18.4% 6.6% 12 
Pneumonia, organism unspecified 486 <0.001 <0.001 18.4% 7.5% 11 
Hematuria, Hemiplegia, or other disorders of urinary tract 599 <0.001 0.008 20.9% 12.0% 9 
Joint, leg or muscle pain; symptoms involving nervous and 
musculoskeletal systems 






















Senility without mention of psychosis 797 <0.001 <0.001 10.0% 0.7% 9 
Neuroses and Personality Disorders including Sleep disorders, 
Tension Headache, Habit Spasms, Enuresis due to mental 
disorder, Anorexia Nervosa 
307 <0.001 <0.001 12.9% 5.0% 8 
Functional digestive disorders, not elsewhere classified 564 <0.001 <0.001 11.9% 4.3% 8 
General symptoms including pyrexia of unknown origin, 
headache, vertigo, ataxia 
780 0.002 0.032 19.9% 12.1% 8 
Nonspecific findings on examination of blood 790 <0.001 <0.001 11.4% 3.8% 8 
Other nonspecific abnormal findings 796 <0.001 0.007 17.4% 9.3% 8 
Benign neoplasm of skin 216 0.002 0.027 17.9% 10.6% 7 
Heart failure 428 <0.001 0.003 11.9% 5.0% 7 
Chronic airway obstruction, not elsewhere classified 496 0.003 0.044 12.9% 7.1% 6 
Myositis, Muscular Rheumatism , Fibrositic, myositis, muscular 
rheumatism... , unspecified neuralgia (7292) 
729 <0.001 <0.001 7.5% 1.3% 6 
Symptoms involving urinary system 788 <0.001 0.004 10.0% 4.0% 6 
Poisoning by other and unspecified drugs and medicinal 
substances 
977 <0.001 0.003 10.0% 3.8% 6 
Other and unspecified disorders of metabolism 277 <0.001 <0.001 6.0% 0.6% 5 






















Other disorders of intestine 569 0.001 0.018 9.0% 3.8% 5 
Other local infections of skin and subcutaneous tissue 686 <0.001 0.004 6.5% 1.9% 5 
Other and ill-defined sprains and strains 848 <0.001 0.011 7.0% 2.5% 5 
Alcohol dependence syndrome 303 <0.001 <0.001 4.0% 0.5% 4 
Diseases of esophagus 530 <0.001 0.015 7.0% 2.6% 4 
Malignant neoplasm of trachea, bronchus, and lung 162 <0.001 0.013 4.0% 0.9% 3 
Parkinson's disease 332 <0.001 0.008 4.0% 0.8% 3 
Benign neoplasm of other and unspecified sites 229 0.003 0.045 3.0% 0.7% 2 
Other nonorganic psychoses 298 <0.001 0.010 2.0% 0.2% 2 
Intestinal obstruction without mention of hernia 560 0.003 0.040 2.5% 0.5% 2 
Fracture of ankle 824 0.001 0.018 3.0% 0.5% 2 
Encephalitis, myelitis, and encephalomyelitis 323 0.001 0.019 1.0% 0.0% 1 





Table B-7 Fisher's Exact test on diagnosis distributions in off-label and reference groups – Imputed Set 3 - Children (Only statistically 
significant results are reported, sorted by the difference in prevalence from those most in excess in the off-label group to those most in 



















Hyperkinetic syndrome of childhood 314 <0.001 0.004 31.2% 2.2% 29 
Other nonorganic psychoses 298 <0.001 0.004 12.5% 0.0% 12 





Table B-8 Fisher's Exact test on diagnosis distributions in off-label and reference groups – Imputed Set 3 - Adult (Only statistically significant 





















Depressive disorder, not elsewhere classified 311 <0.001 <0.001 32.7% 11.0% 22 
Anxiety, dissociative and somatoform disorders 300 <0.001 <0.001 42.5% 23.8% 19 
Drug dependence 304 <0.001 <0.001 10.6% 1.8% 9 
Neuroses and Personality Disorders including Sleep disorders, 
Tension Headache, Habit Spasms, Enuresis due to mental 
disorder, Anorexia Nervosa 
307 <0.001 <0.001 13.1% 4.3% 9 
Joint, leg or muscle pain; symptoms involving nervous and 
musculoskeletal systems 
781 <0.001 <0.001 23.7% 14.7% 9 
Paranoid Personality Disorder; Obessesive Compulsive 
Personality 
301 <0.001 <0.001 5.7% 0.4% 5 
Myositis, Muscular Rheumatism , Fibrositic, myositis, 
muscular rheumatism... , unspecified neuralgia (7292) 
729 <0.001 <0.001 6.0% 0.9% 5 
Drug-induced mental disorders 292 <0.001 <0.001 4.6% 0.2% 4 
Alcohol-induced mental disorders 291 <0.001 <0.001 3.5% 0.2% 3 
Other nonorganic psychoses 298 <0.001 <0.001 2.7% 0.2% 3 






















Other and unspecified anemias 285 <0.001 0.012 1.9% 0.4% 2 
Sexual and gender identity disorders 302 <0.001 0.002 1.9% 0.3% 2 
Alcohol dependence syndrome 303 0.002 0.035 2.2% 0.6% 2 
Other disorders of female genital organs 629 <0.001 0.014 3.0% 0.9% 2 
Symptoms involving urinary system 788 0.003 0.047 4.4% 1.9% 2 
Unspecified intellectual disabilities 319 0.003 0.047 1.1% 0.1% 1 
Tetanus 37 <0.001 0.006 0.0% 2.4% -2 
Disorders of conjunctiva 372 <0.001 0.009 1.1% 4.5% -3 
Disorders of external ear 380 0.002 0.030 0.8% 3.6% -3 
Sprains and strains of ankle and foot 845 0.001 0.022 1.6% 5.1% -3 
Gastritis and duodenitis 535 <0.001 <0.001 0.3% 4.7% -4 
Atopic dermatitis and related conditions 691 <0.001 0.017 2.2% 6.0% -4 
Hirsutism, scar, or other disorders of skin and subcutaneous 
tissue 
709 0.001 0.022 2.5% 6.4% -4 
Other diseases due to viruses and Chlamydiae 78 <0.001 0.001 1.1% 5.2% -4 
Sprains and strains of knee and leg 844 <0.001 0.017 2.7% 6.8% -4 






















Acute nasopharyngitis [common cold] 460 <0.001 <0.001 8.7% 19.7% -11 
Immunization 896 <0.001 <0.001 1.4% 13.4% -12 





Table B-9 Fisher's Exact test on diagnosis distributions in off-label and reference groups – Imputed Set 3 - Seniors (Only statistically significant 





















Anxiety, dissociative and somatoform disorders 300 <0.001 <0.001 46.9% 20.6% 26 
Dementias 290 <0.001 <0.001 23.9% 5.3% 19 
Cardiovascular symptoms including chest pain, tachycardia, 
syncope, shock, edema, masses 
785 <0.001 <0.001 31.5% 14.3% 17 
Digestive symptoms including anorexia, nausea and vomiting, 
heartburn, dysphagia, hiccough, hematemesis, jaundice, 
ascites, abdominal pain, melena, masses 
787 <0.001 <0.001 37.6% 21.6% 16 
Injury, other and unspecified 959 <0.001 <0.001 17.8% 4.3% 14 
adverse effects Of surgical and medical care (e.g., wound 
infection, wound disruption, other iatrogenic disease) 
998 <0.001 <0.001 21.1% 6.9% 14 
Other ill-defined conditions of non-specific abnormal findings 
including asphyxia, excessive sweating, etc. 
799 <0.001 <0.001 30.0% 16.6% 13 
Benign neoplasm of skin 216 <0.001 <0.001 20.7% 10.8% 10 
Depressive disorder, not elsewhere classified 311 <0.001 <0.001 18.3% 7.9% 10 
Pneumonia, organism unspecified 486 <0.001 <0.001 17.8% 7.5% 10 






















Neuroses and Personality Disorders including Sleep disorders, 
Tension Headache, Habit Spasms, Enuresis due to mental 
disorder, Anorexia Nervosa 
307 <0.001 <0.001 14.6% 5.1% 9 
Hematuria, Hemiplegia, or other disorders of urinary tract 599 <0.001 0.008 20.7% 12.2% 8 
Other disorders of synovium, tendon, and bursa 727 <0.001 0.003 16.0% 7.9% 8 
Nonspecific findings on examination of blood 790 <0.001 <0.001 11.7% 3.8% 8 
Other nonspecific abnormal findings 796 <0.001 0.003 17.8% 9.4% 8 
Other disorders of ear 388 0.002 0.020 16.9% 9.8% 7 
Functional digestive disorders, not elsewhere classified 564 <0.001 <0.001 11.7% 4.4% 7 
General symptoms including pyrexia of unknown origin, 
headache, vertigo, ataxia 
780 0.004 0.049 19.2% 12.3% 7 
Iron deficiency anemias 280 <0.001 0.008 9.9% 4.3% 6 
Heart failure 428 <0.001 0.005 11.3% 5.0% 6 
Chronic airway obstruction, not elsewhere classified 496 0.002 0.023 13.1% 7.1% 6 
Other disorders of intestine 569 <0.001 0.005 9.4% 3.8% 6 
Myositis, Muscular Rheumatism , Fibrositic, myositis, muscular 
rheumatism... , unspecified neuralgia (7292) 
729 <0.001 <0.001 7.5% 1.3% 6 






















Ill-defined intestinal infections 9 <0.001 0.009 11.3% 5.3% 6 
Poisoning by other and unspecified drugs and medicinal 
substances 
977 <0.001 0.003 9.9% 3.9% 6 
Other and unspecified malignant neoplasm of skin 173 <0.001 0.007 8.0% 3.1% 5 
Other and unspecified disorders of metabolism 277 <0.001 <0.001 5.6% 0.6% 5 
Migraine 346 <0.001 <0.001 6.1% 1.2% 5 
Diseases of esophagus 530 <0.001 0.005 7.5% 2.7% 5 
Diverticula of intestine 562 0.001 0.014 6.6% 2.5% 4 
Other local infections of skin and subcutaneous tissue 686 <0.001 0.005 6.1% 1.9% 4 
Other and ill-defined sprains and strains 848 <0.001 0.012 6.6% 2.4% 4 
Malignant neoplasm of trachea, bronchus, and lung 162 0.001 0.019 3.8% 1.0% 3 
Parkinson's disease 332 <0.001 0.009 3.8% 0.8% 3 
Secondary malignant neoplasm of other specified sites 198 0.002 0.030 1.9% 0.2% 2 
Other nonorganic psychoses 298 <0.001 0.010 1.9% 0.2% 2 
Alcohol dependence syndrome 303 <0.001 0.011 2.8% 0.5% 2 
Intestinal obstruction without mention of hernia 560 <0.001 0.009 2.8% 0.4% 2 






















Encephalitis, myelitis, and encephalomyelitis 323 0.001 0.019 0.9% 0.0% 1 





Table B-10 Fisher's Exact test on diagnosis distributions in off-label and reference groups – Imputed Set 4 - Children (Only statistically 
significant results are reported, sorted by the difference in prevalence from those most in excess in the off-label group to those most in 




















Anxiety, dissociative and somatoform disorders 300 <0.001 0.013 41.2% 7.8% 33 
Benign neoplasm of skin 216 <0.001 0.013 23.5% 1.4% 22 
Sprains and strains of wrist and hand 842 <0.001 0.013 23.5% 1.7% 22 
Hyperkinetic syndrome of childhood 314 <0.001 0.023 23.5% 2.3% 21 
Depressive disorder, not elsewhere classified 311 <0.001 0.023 17.6% 0.9% 17 
Symptoms involving urinary system 788 <0.001 0.023 17.6% 0.9% 17 
Sprains and strains of shoulder and upper arm 840 <0.001 0.023 17.6% 1.0% 17 
Acquired hypothyroidism 244 <0.001 0.023 11.8% 0.2% 12 
Myositis, Muscular Rheumatism , Fibrositic, myositis, 
muscular rheumatism... , unspecified neuralgia (7292) 
729 <0.001 0.013 11.8% 0.1% 12 





Table B-11 Fisher's Exact test on diagnosis distributions in off-label and reference groups – Imputed Set 4 - Adult (Only statistically significant 





















Depressive disorder, not elsewhere classified 311 <0.001 <0.001 32.0% 11.1% 21 
Anxiety, dissociative and somatoform disorders 300 <0.001 <0.001 42.0% 23.9% 18 
Neuroses and Personality Disorders including Sleep disorders, 
Tension Headache, Habit Spasms, Enuresis due to mental 
disorder, Anorexia Nervosa 
307 <0.001 <0.001 13.6% 4.3% 9 
Joint, leg or muscle pain; symptoms involving nervous and 
musculoskeletal systems 
781 <0.001 <0.001 23.8% 14.6% 9 
Drug dependence 304 <0.001 <0.001 10.3% 1.8% 8 
Paranoid Personality Disorder; Obessesive Compulsive 
Personality 
301 <0.001 <0.001 5.4% 0.4% 5 
Myositis, Muscular Rheumatism , Fibrositic, myositis, muscular 
rheumatism... , unspecified neuralgia (7292) 
729 <0.001 <0.001 5.7% 1.0% 5 
Drug-induced mental disorders 292 <0.001 <0.001 4.6% 0.2% 4 
Alcohol-induced mental disorders 291 <0.001 <0.001 3.5% 0.2% 3 
Other nonorganic psychoses 298 <0.001 <0.001 3.0% 0.2% 3 






















Sexual and gender identity disorders 302 <0.001 0.002 1.9% 0.3% 2 
Alcohol dependence syndrome 303 0.002 0.040 2.2% 0.6% 2 
Other disorders of female genital organs 629 <0.001 0.004 3.3% 0.9% 2 
Other and unspecified anemias 285 0.002 0.043 1.6% 0.4% 1 
Unspecified intellectual disabilities 319 0.003 0.044 1.1% 0.1% 1 
Tetanus 37 <0.001 0.006 0.0% 2.4% -2 
Acute tonsillitis 463 <0.001 0.008 0.0% 2.3% -2 
Dyspareunia, dysmenorrhea, premenstrual tension, stress 
incontinence 
625 0.002 0.039 0.3% 2.5% -2 
Disorders of conjunctiva 372 <0.001 0.008 1.1% 4.6% -3 
Other cellulitis and abscess 682 0.002 0.033 0.8% 3.6% -3 
Sprains and strains of ankle and foot 845 0.003 0.044 1.9% 5.2% -3 
Atopic dermatitis and related conditions 691 <0.001 0.006 1.9% 6.1% -4 
Hirsutism, scar, or other disorders of skin and subcutaneous 
tissue 
709 0.002 0.043 2.7% 6.4% -4 
Other diseases due to viruses and Chlamydiae 78 <0.001 <0.001 0.8% 5.2% -4 
Sprains and strains of knee and leg 844 0.002 0.042 3.0% 6.8% -4 






















Family Planning 895 0.003 0.047 5.1% 9.5% -4 
Gastritis and duodenitis 535 <0.001 <0.001 0.0% 4.7% -5 
Acute bronchitis and bronchiolitis 466 <0.001 <0.001 4.6% 11.4% -7 
Acute nasopharyngitis [common cold] 460 <0.001 <0.001 7.6% 19.9% -12 
Immunization 896 <0.001 <0.001 1.4% 13.3% -12 





Table B-12 Fisher's Exact test on diagnosis distributions in off-label and reference groups – Imputed Set 4 - Seniors (Only statistically 
significant results are reported, sorted by the difference in prevalence from those most in excess in the off-label group to those most in 




















Anxiety, dissociative and somatoform disorders 300 <0.001 <0.001 46.7% 20.6% 26 
Dementias 290 <0.001 <0.001 24.8% 5.3% 19 
Cardiovascular symptoms including chest pain, tachycardia, 
syncope, shock, edema, masses 
785 <0.001 <0.001 32.4% 14.2% 18 
Digestive symptoms including anorexia, nausea and vomiting, 
heartburn, dysphagia, hiccough, hematemesis, jaundice, 
ascites, abdominal pain, melena, masses 
787 <0.001 <0.001 37.6% 21.5% 16 
Other ill-defined conditions of non-specific abnormal findings 
including asphyxia, excessive sweating, etc. 
799 <0.001 <0.001 31.9% 16.3% 16 
adverse effects Of surgical and medical care (e.g., wound 
infection, wound disruption, other iatrogenic disease) 
998 <0.001 <0.001 21.4% 6.8% 15 
Injury, other and unspecified 959 <0.001 <0.001 18.6% 4.3% 14 
Pneumonia, organism unspecified 486 <0.001 <0.001 18.6% 7.5% 11 
Depressive disorder, not elsewhere classified 311 <0.001 <0.001 18.1% 7.8% 10 






















Neuroses and Personality Disorders including Sleep disorders, 
Tension Headache, Habit Spasms, Enuresis due to mental 
disorder, Anorexia Nervosa 
307 <0.001 <0.001 13.8% 5.0% 9 
Hematuria, Hemiplegia, or other disorders of urinary tract 599 <0.001 0.005 21.0% 12.1% 9 
General symptoms including pyrexia of unknown origin, 
headache, vertigo, ataxia 
780 <0.001 0.005 21.4% 12.3% 9 
Other nonspecific abnormal findings 796 <0.001 0.002 18.1% 9.4% 9 
Benign neoplasm of skin 216 <0.001 0.007 19.0% 10.7% 8 
Other disorders of ear 388 <0.001 0.007 17.6% 9.7% 8 
Functional digestive disorders, not elsewhere classified 564 <0.001 <0.001 12.9% 4.4% 8 
Nonspecific findings on examination of blood 790 <0.001 <0.001 11.4% 3.8% 8 
Other disorders of synovium, tendon, and bursa 727 <0.001 0.005 15.2% 7.7% 7 
Migraine 346 <0.001 <0.001 7.1% 1.1% 6 
Heart failure 428 <0.001 0.004 11.4% 5.0% 6 
Diseases of esophagus 530 <0.001 <0.001 8.6% 2.7% 6 
Other disorders of intestine 569 <0.001 0.001 10.0% 3.7% 6 
Myositis, Muscular Rheumatism , Fibrositic, myositis, muscular 
rheumatism... , unspecified neuralgia (7292) 






















Symptoms involving urinary system 788 <0.001 0.001 10.5% 4.0% 6 
Ill-defined intestinal infections 9 <0.001 0.008 11.4% 5.3% 6 
Other and unspecified malignant neoplasm of skin 173 <0.001 0.007 8.1% 3.1% 5 
Other and unspecified disorders of metabolism 277 <0.001 <0.001 5.7% 0.6% 5 
Iron deficiency anemias 280 <0.001 0.010 9.5% 4.2% 5 
Other local infections of skin and subcutaneous tissue 686 <0.001 0.002 6.7% 1.9% 5 
Poisoning by other and unspecified drugs and medicinal 
substances 
977 <0.001 0.011 9.0% 3.8% 5 
Other and ill-defined sprains and strains 848 0.002 0.026 6.2% 2.4% 4 
Malignant neoplasm of trachea, bronchus, and lung 162 0.001 0.015 3.8% 0.9% 3 
Alcohol dependence syndrome 303 <0.001 0.002 3.3% 0.5% 3 
Parkinson's disease 332 <0.001 0.007 3.8% 0.8% 3 
Other and unspecified disorders of the nervous system 349 0.003 0.031 3.8% 1.1% 3 
Other nonorganic psychoses 298 <0.001 0.007 1.9% 0.1% 2 
Paranoid Personality Disorder; Obessesive Compulsive 
Personality 
301 <0.001 0.008 1.9% 0.2% 2 
Intestinal obstruction without mention of hernia 560 <0.001 0.008 2.9% 0.5% 2 



























Table B-13 Fisher's Exact test on diagnosis distributions in off-label and reference groups – Imputed Set 5 - Children (Only statistically 
significant results are reported, sorted by the difference in prevalence from those most in excess in the off-label group to those most in 



















Other and unspecified disorders of back 724 <0.001 0.007 26.7% 1.3% 25 
Hyperkinetic syndrome of childhood 314 <0.001 0.027 26.7% 2.2% 24 
Menopausal and postmenopausal 
disorders 
627 <0.001 0.007 13.3% 0.0% 13 





Table B-14 Fisher's Exact test on diagnosis distributions in off-label and reference groups – Imputed Set 5 - Adult (Only statistically significant 





















Depressive disorder, not elsewhere classified 311 <0.001 <0.001 31.3% 11.1% 20 
Anxiety, dissociative and somatoform disorders 300 <0.001 <0.001 42.7% 23.8% 19 
Neuroses and Personality Disorders including Sleep disorders, 
Tension Headache, Habit Spasms, Enuresis due to mental 
disorder, Anorexia Nervosa 
307 <0.001 <0.001 13.3% 4.3% 9 
Joint, leg or muscle pain; symptoms involving nervous and 
musculoskeletal systems 
781 <0.001 <0.001 23.9% 14.7% 9 
Drug dependence 304 <0.001 <0.001 10.1% 1.8% 8 
Paranoid Personality Disorder; Obessesive Compulsive 
Personality 
301 <0.001 <0.001 5.3% 0.4% 5 
Myositis, Muscular Rheumatism , Fibrositic, myositis, 
muscular rheumatism... , unspecified neuralgia (7292) 
729 <0.001 <0.001 6.1% 0.9% 5 
Drug-induced mental disorders 292 <0.001 <0.001 4.5% 0.2% 4 
Cardiovascular symptoms including chest pain, tachycardia, 
syncope, shock, edema, masses 
785 0.002 0.048 10.9% 6.7% 4 
Alcohol-induced mental disorders 291 <0.001 <0.001 3.4% 0.2% 3 






















Specific delays in development 315 <0.001 <0.001 3.7% 0.5% 3 
Poisoning by other and unspecified drugs and medicinal 
substances 
977 <0.001 0.015 4.2% 1.6% 3 
Sexual and gender identity disorders 302 <0.001 0.002 1.9% 0.3% 2 
Other disorders of female genital organs 629 <0.001 0.005 3.2% 0.9% 2 
Other and unspecified anemias 285 <0.001 0.015 1.9% 0.4% 1 
Tetanus 37 <0.001 0.006 0.0% 2.4% -2 
Disorders of conjunctiva 372 <0.001 0.002 0.8% 4.6% -4 
Gastritis and duodenitis 535 <0.001 0.005 1.1% 4.7% -4 
Atopic dermatitis and related conditions 691 0.002 0.039 2.4% 6.0% -4 
Hirsutism, scar, or other disorders of skin and subcutaneous 
tissue 
709 0.001 0.030 2.7% 6.4% -4 
Other diseases due to viruses and Chlamydiae 78 <0.001 0.001 1.1% 5.2% -4 
Family Planning 895 0.002 0.039 5.0% 9.5% -4 
Acute bronchitis and bronchiolitis 466 <0.001 <0.001 5.0% 11.4% -6 
Acute nasopharyngitis [common cold] 460 <0.001 <0.001 8.8% 19.8% -11 
Immunization 896 <0.001 <0.001 1.3% 13.3% -12 







Table B-15 Fisher's Exact test on diagnosis distributions in off-label and reference groups – Imputed Set 5 - Seniors (Only statistically 
significant results are reported, sorted by the difference in prevalence from those most in excess in the off-label group to those most in 




















Anxiety, dissociative and somatoform disorders 300 <0.001 <0.001 46.1% 20.7% 25 
Dementias 290 <0.001 <0.001 25.0% 5.3% 20 
Cardiovascular symptoms including chest pain, 
tachycardia, syncope, shock, edema, masses 
785 <0.001 <0.001 29.9% 14.2% 16 
Digestive symptoms including anorexia, nausea and 
vomiting, heartburn, dysphagia, hiccough, hematemesis, 
jaundice, ascites, abdominal pain, melena, masses 
787 <0.001 <0.001 36.8% 21.6% 15 
Injury, other and unspecified 959 <0.001 <0.001 19.1% 4.4% 15 
adverse effects Of surgical and medical care (e.g., 
wound infection, wound disruption, other iatrogenic 
disease) 
998 <0.001 <0.001 19.6% 6.8% 13 
Pneumonia, organism unspecified 486 <0.001 <0.001 19.1% 7.6% 12 
Other ill-defined conditions of non-specific abnormal 
findings including asphyxia, excessive sweating, etc. 
799 <0.001 <0.001 28.9% 16.4% 12 
Depressive disorder, not elsewhere classified 311 <0.001 <0.001 19.1% 7.8% 11 






















Neuroses and Personality Disorders including Sleep 
disorders, Tension Headache, Habit Spasms, Enuresis 
due to mental disorder, Anorexia Nervosa 
307 <0.001 <0.001 14.2% 4.9% 9 
Hematuria, Hemiplegia, or other disorders of urinary 
tract 
599 <0.001 0.005 21.6% 12.2% 9 
Other nonspecific abnormal findings 796 <0.001 0.002 18.1% 9.3% 9 
Benign neoplasm of skin 216 <0.001 0.015 18.6% 10.8% 8 
Other disorders of ear 388 0.003 0.037 16.7% 9.8% 7 
Heart failure 428 <0.001 0.003 11.8% 5.0% 7 
Functional digestive disorders, not elsewhere classified 564 <0.001 <0.001 11.8% 4.4% 7 
Symptoms involving urinary system 788 <0.001 <0.001 11.3% 4.0% 7 
Other disorders of synovium, tendon, and bursa 727 0.001 0.022 14.2% 7.7% 6 
Myositis, Muscular Rheumatism , Fibrositic, myositis, 
muscular rheumatism... , unspecified neuralgia (7292) 
729 <0.001 <0.001 7.4% 1.3% 6 
Nonspecific findings on examination of blood 790 <0.001 0.001 10.3% 3.8% 6 
Ill-defined intestinal infections 9 0.001 0.022 10.8% 5.2% 6 
Other and unspecified disorders of metabolism 277 <0.001 <0.001 5.4% 0.6% 5 






















Migraine 346 <0.001 <0.001 5.9% 1.1% 5 
Other disorders of intestine 569 0.003 0.036 8.3% 3.8% 5 
Other local infections of skin and subcutaneous tissue 686 <0.001 0.001 6.9% 1.9% 5 
Diseases of esophagus 530 0.002 0.024 6.9% 2.7% 4 
Other and ill-defined sprains and strains 848 <0.001 0.009 6.9% 2.4% 4 
Malignant neoplasm of trachea, bronchus, and lung 162 <0.001 0.015 3.9% 0.9% 3 
Alcohol dependence syndrome 303 <0.001 <0.001 3.9% 0.5% 3 
Parkinson's disease 332 <0.001 0.009 3.9% 0.8% 3 
Secondary malignant neoplasm of other specified sites 198 0.002 0.032 2.0% 0.2% 2 
Paranoid Personality Disorder; Obessesive Compulsive 
Personality 
301 <0.001 0.011 2.0% 0.2% 2 
Intestinal obstruction without mention of hernia 560 <0.001 0.010 2.9% 0.5% 2 
Encephalitis, myelitis, and encephalomyelitis 323 0.001 0.021 1.0% 0.0% 1 
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